Skip to main content
Navigate Up
Sign In

Clinical Trials Search

If you are a researcher seeking volunteers and your study is not posted, please submit your Web ad here.

SEARCH

Search Again

 Results From Research and Clinical Trials : Selected site
TitleStudy GoalsEligibility CriteriaContact Information
Diabetic Male and Female Volunteers Needed for Exercise Research Study 06-0062
Evaluate exercise function during single leg calf exercise in people with or without type 2 diabetes
Healthy Adults 30-70 with Type 2 diabetes but not using insulin. Must be a non-smoker who exercise no more than one time per week and have a BMI of 25-40
PI: Regensteiner, Judith
  • 303-724-2255
  • Deirdre.rafferty@ucdenver.edu
Persons with active, moderate to severe ulcerative colitis needed 12-1408
This study is being conducted to investigate the efficacy of methotrexate in treating ulcerative colitis in patients that have active, moderate to severe colitis and have failed other types of therapies.
Inclusion: Ages 18-70 Ulcerative colitis has been diagnoses by routine criteria At least one of the following applies: steroid dependent failed 5-ASA (mesalamine) therapy, such as Asacol Failed/lost response to infliximab (Remicade) Intolerant/unresponsive to azathioprine (Imuran) or 6-MP (purinethol) therapy Exclusion (partial): Existing pregnancy, lactation, or planned pregnancy (men and women)
PI: Gerich, Mark
  • 303-724-7875
  • katelyn.cowan@ucdenver.edu
Do you or someone you know have a food allergy to soy? 14-0097
We are studying the accuracy of a food allergy blood test.  
-Are age 1 to 21 and -Do have an IgE level greater than 0.35 to wheat OR soy or -Have had a positive skin test to wheat OR soy or -Have a clinically diagnosed wheat OR soy allergy -Do NOT use >500 micrograms/day fluticasone or equivalent -Do NOT have severe asthma, daily oral steroid dosing, or asthma requiring hospitalization within a year or an ER visit in the past 6 months -Do NOT have active EoE (or recently diagnosed) -Have NOT used biologic or allergen immunotherapy within the past year
PI: Fleischer, David
  • 720-777-2569
  • Hannah.Gilbert@childrenscolorado.org
Participants Needed For Research on Military Veterans And Service Dogs 14-2041
The purpose of this study is to explore the relationship between military veterans and their service dogs. Veterans will participate in one on one interviews.
Are you a military veteran? Do you have a service dog? Are you 18-89 years old? If you answered yes to the above, contact C-P.A.W.W. today.
PI: Krause-Parello, Cheryl
  • 303-724-8282
  • CPAWW@ucdenver.edu
Do you have HIV and lipodystrophy? 14-1595
Our research aims to determine whether the development of Lipodystrophy Syndrome is related to changes in the types of bacteria that live in the gut (stool) that occur in HIV-infected individuals.
Non-obese HIV-positive people who are 18-70 years old. Exhibiting the symptoms described above, indicating the possibility of lipodystrophy.
PI: Lozupone, PhD, Catherine
  • 303-724-0762
  • christine.griesmer@ucdenver.edu
Type 1 Diabetes Research Study 15-1309
The purpose of this research study is to evaluate the effects of an FDA-approved medication (bromocriptine QR) on insulin dosing, glucose control, and blood vessel function.
Persons 18-60 with Type 1 Diabetes, Non-smokers
PI: Schauer, Irene
  • 720-848-6690
  • ellen.lyon@ucdenver.edu
We are looking for MEN who have not been diagnosed with cancer to participate in a research study. 11-0357
A comparison of immune function from unaffected individuals for the study of tumor-induced immune suppression
To participate you must: -Older than 18 -Be willing to make a one-time blood donation -Not be diagnosed with an immune disease such as diabetes, hepatitis or rheumatoid arthritis You could make a difference in the future of men!
PI: Borges, Virginia
  • 303-724-6077
  • emily.rozzo@ucdenver.edu
Participants needed for a Balance and Fall-Risk Research Study for People with Multiple Sclerosis 15-1806
This study involves balance and head movement testing aimed at predicting risk of falls
Are between the ages of 30 and 60 years
• have MS
• are able to turn your head at least 30 degrees to the left,
• have experienced a fall in the last 3 months
PI: Hebert, Jeffrey
  • 303-724-4717
  • molly.strobel@ucdenver.edu
Healthy Adults Needed for Clinical Research Study 15-1643
The purpose of this study is to learn about the effects (good and bad) of interferon-gamma 1b (IFN-γ 1B) has on the body's immune cells when given to healthy adults.
Ages ≥ 18 to 60 years old Has not received IFN-γ within the last 30 days of study enrollment At the time of screening, deemed healthy by the Principal Investigator with no active infections and is not currently receiving medications for an infection No diagnosis of chronic health conditions or is on long-term medications for that condition Women of childbearing potential must have a negative pregnancy test to qualify and agree to two forms of effective contraception for the duration of the study (plus one month afterward)
PI: Ambruso, Daniel
  • 303-324-2171
  • daniel.ambruso@ucdenver.edu
Volunteers Needed for blood donation for research and development. WIRB 20110239
To gain knowledge relating to the collection, storage and product modifications of whole blood, apheresis units, and various blood components as well as the function and biochemistry of various types of blood cells.
YOU MAY QUALIFY TO DONATE IF YOU: -Are at least 18 years old -Weigh 110 pounds or more -Are in good general health -Can attend appointment(s) during the week
PI: Le, Tuan
  • 303-363-2300
  • Lisa_Sherritt@Bonfils.org
SPIROMICS-Subpopulations and Intermediate Outcome Measures in COPD Study HS-2678
To identify subpopulations of COPD patients in order to develop newer and more effective treatments and to clearly define measureable end points so that treatment effects may be accurately assessed in a shorter period of time.
Be willing to undergo study procedures Be between the age of 40 and 80 years old Have smoked fewer than one pack of cigarettes per day for one year OR have smoked more than one pack of cigarettes per day for 20 years
PI: Bowler, Russell
  • 303-270-2827
  • HerrudT@njHealth.org
Healthy Female Adolescents Needed!!! 07-0816
For brain imaging research study on how the brain works with we taste sweets or receive money. Your participation could help us to develop treatments and preventive measures for anorexia nervosa and obesity
Healthy females 11 to 21 who are right-handed, free of medication with no serious medical conditions, permanent metal implants or braces/retainers, and are at a healthy body weight.
PI: Frank, Guido
  • 720-777-4026
  • imaging.research@childrenscolorado.org
A Study to Determine the Effectiveness of Seeing Dermatologist Online Compared to In-Person 14-0585
The purpose of the study is to see whether seeing a dermatologist online is just as effective as seeing one in-person. Help us determine whether online-based model is cost-saving and more efficient compared to face-to-face visits!
In order to qualify for the study, you must be 18 years or older and have psoriasis. You must have access to the internet, and a digital camera or a mobile phone with a camera.
PI: Dunnick, Cory
  • 720-848-3607
  • psoriasiscolorado@ucdenver.edu
Do You or Someone You Care for Suffer from Troublesome Drooling? 13-2237
A research study is being conducted to evaluate an investigational product for Sialorrhea (troublesome drooling).
You or your loved one may be eligible to participate if you meet the following criteria: 1. Have a diagnosis of Parkinson’s disease, adult cerebral palsy, ALS, stroke, traumatic brain injury, oral cancer, or side effects of medication, or any other condition that causes Sialorrhea or troublesome drooling 2. Have never received any type of treatment using Botulinum toxin type B 3. Have ability & availability to participate in a study for up to 1 year
PI: Klepitskaya, Olga
  • 303-724-8305
  • kalie.petefish@ucdenver.edu
Parkinson's Disease Research Study 14-0879
clinical research study to look at the safety and effectiveness of an investigational medication, ADS-5102 (amantadine HCl) extended release capsules, for troublesome dyskinesia in subjects with Parkinson’s disease.
You may be eligible if you have Parkinson's Disease, currently take levodopa, and are experiencing troublesome dyskinesia (involuntary twisting and turning).
PI: Leehey, Maureen
  • 303-724-8305
  • Kalie.Petefish@ucdenver.edu
Type 2 Diabetes Medication Research Study 13-2015
Studying the effects of sitagliptin (a diabetes medication) on exercise capacity in people with type 2 diabetes
-Be a man or woman between 22 and 70 years old -Be generally healthy, with type 2 diabetes -Be taking metformin only for your diabetes -Be a non-smoker -Have a Body Mass Index greater than 25.0
PI: Regensteiner, Judith
  • 303-724-2255
  • Deirdre.rafferty@ucdenver.edu
Research study to investigate how therapies work to reduce tension-type headache 14-1582
To understand how massage or ultrasound therapies affect blood flow within myofascial trigger points that are related to chronic pain such as tension-type headache.
Persons aged 21-49 who experience chronic or episodic tension-type headache and are not currently receiving massage, ultrasound, trigger point injection, or needling therapies.
PI: Moraska, Albert
  • 303-819-1834
  • albert.moraska@ucdenver.edu
" EDEN "Estrogen, Diabetes and Endothelial Function 10-0591
Study the effect of estrogen on blood vessels
CONTROL PARTICIPANT ELIGIBILITY · Age 18-45 · Premenopausal · Not using hormonal birth control currently or in the last 6 months (including oral contraceptives, contraceptive patch, Depo Provera, norplant, or IUD) · Not currently pregnant or planning to become pregnant in the next 3 months · No recent history of amenorrhea (no menstrual period for at least 3 months) during the last 6 months · Non-smoker · No antioxidant therapy (vitamin C or E or multivitamin) for at least 4 weeks prior to the first study visit   Normal thyroid function (can be treated)  T1D ELIGIBILITY  · Age 18-45 · Premenopausal · Have had type 1 diabetes for at least 5 years, were treated with insulin within a year of diagnosis, and are currently treated with insulin · Not using hormonal birth control currently or in the last 6 months (including oral contraceptives, contraceptive patch, Depo Provera, norplant, or  IUD) · Not currently pregnant or planning to become pregnant in the next 3 months · No recent history of amenorrhea (no menstrual period for at least 3 months) during the last 6months · Non-smoker · No antioxidant therapy (vitamin C or E or multivitamin) for at least 4 weeks prior to the first study visit  HbA1c < 9.5  Normal kidney function (urinary albumin excretion rate < 200 µg/min)         Normal thyroid function (can be treated)
PI: Snell-Bergeon, Janet
  • 303-724-6899
  • Caprice.sassano@ucdenver.edu
Rhythmic Enhancement of Motor Performance 15-0286
It is known that people with Parkinson's Disease are able to move better with music or rhythm. This research study plans to learn more about he areas of the brain that react to rhythm in people with Parkinson's Disease (PD) and healthy older adults.
Healthy male older controls aged 55-85.
PI: Kluger, Benzi
  • 303-724-6351
  • Nicola.haakonsen@ucdenver.edu
Volunteers needed for functional MRI research study 14-1282
Patients with schizophrenia are needed for a research study to learn more about how drugs used to treat illness symptoms affect weight gain and brain responses to food. We are also studying how exercise and diet affect these responses.
Diagnosis of schizophrenia/schizoaffective disorder; taking risperidone, olanzapine, or clozapine; capable of mild/moderate exercise; BMI less than 39; no heart problems or untreated high blood pressure; capable of MRI
PI: Tregellas, Jason
  • 303-724-8299
  • benjamin.lawful@ucdenver.edu
Attention Teens! Are You Concerned About Gaining Too Much Weight During Pregnancy? 14-1505
A research study at Children’s Hospital Colorado and Colorado State University seeks pregnant teenagers age 13-19y who may be at risk for gaining too much weight during pregnancy. Consider participating in this research study focused on testing a healthy pregnant weight gain program. The study involves 1 screening visit, 6 1-hour sessions during pregnancy or usual care, and follow-up visits within 3 months of having your baby. Eligible participants could be financially compensated up to $200-$250 for their time and inconvenience.
Female 13-19 years old Pregnant
PI: Sheeder, Jeanelle
  • 970-236-6317
  • bernadette.pivarunas@childrenscolorado.org
We are looking for Healthy Women to participate in a research study on.....Females, Aging, Metabolism, and Exercise (FAME) 12-1157
To examine the role that female sex hormones play in metabolism, energy expenditure, physical activity and chronic disease.
Healthy women 40-60 who have regular menstrual cycles and using no hormonal contraceptives
PI: Kohrt, Wendy
  • 720-848-6399
  • FAMEStudy@ucdenver.edu
Do you have Diabetes? 13-0131
To find the best combination drug treatment for type 2 diabetes
Persons who have had diabetes for less than 5 years and metformin is the only diabetes medication you are taking.
PI: Rasouli, Neda
  • 720-848-7174
  • Bradley.wine@ucdenver.edu
Type 1 Diabetes Research Study 11-0693
To study the effects of an FDA-approved medication on metabolism and blood vessel function.
Person 25-50 with type 1 diabetes who exercise vigorously less than four times per week and have normal blood pressure
PI: Schauer, Irene
  • 720-848-6690
  • Ellen.Lyon@ucdenver.edu
CHILDHOOD and ADOLESCENT MIGRAINE PREVENTION STUDY 12-0776
to test two medicines for migraine prevention in children and teens. We want to see if amitriptyline and/or topiramate are better than placebo (sugar pill) in reducing headache frequency.
Children 8-17 who have migraine headaches
PI: Kedia, Sita
  • 720-777-8588
  • headacheresearch@childrenscolorado.org
Just received VARIVAX, the chickenpox vaccine? 13-2122
Research study looking at the immune response to chickenpox vaccine
Age 12 months to 50 years; able to enroll in study within 10 days of vaccination.
PI: Levin, Myron
  • 303-724-2454
  • nancy.lang@ucdenver.edu
Healthy Hispanic Female Needed 07-0816
For brain imaging research study on how the brain works with we taste sweets. Your participation could help us to develop treatments and preventive measures for anorexia nervosa and obesity
Healthy females 22 to 29 who are right-handed, free of medication with no serious medical conditions, permanent metal implants or braces/retainers, and are at a healthy body weight.
PI: Frank, Guido
  • 720-777-4026
  • imaging.research@childrenscolorado.org
Looking for HIV-positive individuals to participate in a research study on Lipodystrophy Syndrome 14-1595
We are conducting a study of the relationship of bacteria in the gut to HIV infection. We are interested in finding out whether people who have metabolic diseases such as lipodystrophy (loss of fat tissue) as complications of long term antiretroviral therapy have a different makeup of their gut bacteria. We are therefore seeking volunteers with HIV infection to participate in a study of bacteria in the stool.
-Non-obese HIV positive individuals who are 18-65 years old -Either not currently on antiretroviral therapy (ART naïve or off therapy for 6 months or greater) or on effective ART with documented suppression for 6 months or greater. -We are particularly interested in enrolling subjects with lipodystrophy, but would also like to enroll individuals without lipodystrophy as controls.
PI: Lozupone, PhD, Catherine
  • 303-724-0762
  • christine.griesmer@ucdenver.edu
Looking for HIV-positive and HIV-negative men to participate in a research study on smoking and lung disease 13-2986
We are conducting a study to look at lung complications and disease in HIV/AIDS.
-Between 30 and 70 years old -Both HIV-positive and HIV-negative individuals with and without chronic obstructive pulmonary disease (COPD) -If HIV-positive, on a stable three-drug ART regimen with undetectable viral load for past 6 months
PI: Campbell, MD, Thomas
  • 303-724-0762
  • christine.griesmer@ucdenver.edu
GENETIC-AF 14-0736
The GENETIC-AF is a trial that will investigate the safety and effectiveness of an investigational drug on the recurrence of symptomatic atrial fibrillation in people who have heart failure. The investigational drug will be studied versus an approved drug after patients receive an electrical cardioversion.
Adults who have symptomatic atrial fibrillation may be eligible.
PI: Aleong, Ryan
  • 303-724-8277
  • Christina.schmitt@ucdenver.edu
Healthy Volunteers Needed 10-1311
To examine the differences in two subtypes of Parkinson Disease compared to health controls. This study involves an MRI.
- Between the ages of 50-80 - No metal in your body - In general good health
PI: Berman, Brian
  • 303-724-5865
  • erika.shelton@ucdenver.edu
Interested in Weight Loss? 14-0383
We are researching an investigational device for weight loss in overweight or obese subjects. The device is taken in pill form in two doses daily and may help decrease food intake.
*Are between 22 – 65 years old *Are overweight or obese (a BMI ≥27 and ≤40) - Check your BMI at http://www.nhlbisupport.com/bmi/ *Are willing to participate in regular study visits at the Anschutz Medical Campus
PI: Hill, James
  • 303-724-9198
  • wellness.research@ucdenver.edu
Do you need Emergency Contraception? Sexually Active Women needed for research. 15-0468
We are interested in evaluating the progesterone intrauterine device (IUD) as a method of emergency contraception to prevent pregnancy after unprotected sex.
You might be eligible if you: - Are 18-45 years of age - Have had unprotected sex in the last 5 days - Have had a lapse in your birth control such as a missed pill, forgot your shot, condom broke, etc.
PI: Teal, Stephanie
  • 720-505-1710
  • Shara.Evans@ucdenver.edu
Information for patients. Living with diabetes is complicated. 15-2154
The FREEDOM-3S Study is a clinical research study that will involve approximately 126 patients in the United States. It will look at a potential new treatment option, the ITCA 650,for people with type 2 diabetes. The ITCA 650 is a small metal cylinder (about the size of a matchstick) that is placed under the skin of the abdomen (belly) to slowly release the study medication – exenatide. The FREEDOM-3S Study is looking at how safe and well tolerated two different doses of the ITCA 650 are in people with type 2 diabetes who are already taking liraglutide (also known as Victoza injections, and metformin.
You may be eligible to take part if you: • are 18–80 years of age • have been diagnosed with type 2 diabetes for at least 3 months • have been taking liraglutide (Victoza) injections and metformin every day for at least 3 months.
PI: Rasouli, Neda
  • 720-848-5596
  • Hoda.Farajpour@ucdenver.edu
Controlling blood glucose levels. Can be a real balancing act. 15-1439
The EASE-3 clinical research study is a study in which doctors hope to learn: • Whether the investigational medicine is safe to use in treating type 1 diabetes. • Whether adding the investigational medicine is more effective in controlling blood glucose than insulin alone.
You may be able to join this study if you: • Are 18 years of age or older and you have had insulin-dependent type 1 diabetes for at least a year. • Are willing to take a study medicine in addition to your insulin therapy. • Have an HbA1c level that falls within the range required by the study. • Have a good understanding of your disease and the ability to manage it and are willing to undergo study assessments.
PI: Rasouli, Neda
  • 720-848-1852
  • Yusra.Azhar@ucdenver.edu
The Hot Flash Study 16-0214
Our team is evaluating non-hormonal investigational medication, to see if it helps reduce the frequency and severity of hot flashes in post menopausal women ages 40 to 65
Have gone through menopause Are between the ages of 40 and 65 Are extremely bothered by frequent hot flashes Are willing to keep a record of your daily hot flashes (a handheld electronic diary similar to a smart phone will be provided to help you do this)
PI: Santoro, Nanette
  • 303-724-9643
  • kelsey.jones@ucdenver.edu
Do you have headaches? 15-0983
The University of Colorado is participating in a research study to determine if thoracic spine thrust manipulation alone is beneficial in the treatment of cervicogenic headaches. This project will see if this treatment can aid in reducing pain from these headaches.
You may be eligible to participate in this study if you answer yes to the following questions: - Do you have headaches that are mostly on one side which are associated with neck pain? - Are these headaches worse with movement or certain neck positions? - Do you have these headaches at least once a week for at least the last 2 months? - Are you between 18-60 years of age? - Can you come to physical therapy up to 6 times within a 30 day period? You may be ineligible to participate in this study if you have: - Rheumatoid arthritis - Osteoporosis - Broken bones in your neck or shoulder - A prolonged history of steroid use - A history of whiplash injury within the past six weeks
PI: McDevitt , Amy
  • 3037241906
  • amy.mcdevitt@ucdenver.edu
EFFECTS OF TESTOSTERONE THERAPY IN YOUNG ADOLESCENTS WITH KLINEFELTER SNDROME (47.XXY) 11-0874
This study will study the effects of testosterone therapy on behavior, mood, problem solving, attention span, and motor skills in adolescent males with Klinefelter syndrome in early puberty. During this period in early puberty there is a lot of variability in how and when doctors start testosterone therapy. This study will evaluate if there are benefits to starting testosterone therapy in early puberty.
Participants with Klinefelter syndrome in early puberty (around age 10-15).
PI: Tartaglia, Nicole
  • 720-777-8361
  • susan.howell@childrenscolorado.org
Volunteers with Alzheimer’s Disease Needed for Memory Study 12-1273
To examine the safety and efficacy of the study drug, Sargramostim (Leukine®), on memory in adults with Mild-to-Moderate Alzheimer’s Disease.
1. Age 55 to 85 years; 2. Should have a mild-to-moderate Alzheimer's Disease diagnosis (Mini-Mental State Examination 10-26 inclusive); 3. If on anti-dementia treatment should be on stable treatment for at least 2 months (i.e. cholinesterase inhibitor and/or Memantine or Axona); 4. Stable on all other medications for at least 30 days prior to screen; 5. Should be fluent in English; 6. Should be physically able to participate by medical history, clinical exam and tests; 7. Should have a study partner to accompany them to scheduled visits.
PI: Potter, Huntington
  • 303-724-2997
  • joseph.daniels@ucdenver.edu
T•A•C•I•T - Therapy After Cochlear Implants Using Telemedicine 12-1103
This research plans to learn more about the use of telemedicine as a means of providing therapy to children who have a cochlear implant(s). While Auditory-Verbal Therapy has typically been delivered in person, many people are starting to access therapy over the internet. We are conducting this research to determine if the outcomes of therapy are the same when AVT is delivered in person and via telemedicine.
The TA•C•I•T team is looking for children ages 6 mos.-6 yrs. old who were implanted with cochlear implant(s) before age  3 ½..  Each child will spend nine months in both the in-person and telemedicine condition. The therapist will remain the same throughout the study. Total participation will last 18 months. The child will be tested three times: once when the study starts, and every nine months after that. A qualified study team member will administer speech, listening, and language tests to the child. They will also receive tests to identify how well their auditory area of the brain is developing.
PI: Grigsby, Jim
  • 303-556-5804
  • tacit@ucdenver.edu
Participants with Chronic Kidney Disease Needed for a Research Study about Phosphate 13-0328
We are looking for men and women to participate in a research study examining whether lowering blood levels of phosphate will improve blood vessel function.
We need men and women who:  -are age 40-79 years old; women must be post-menopausal;  -have chronic kidney disease stage 3b or 4 (estimated GFR 15-45 ml/min);  -are not taking phosphate binders;  -do not have high blood phosphate (>5.5 mg/dL).
PI: Jovanovich, Anna
  • 303-724-7790
  • mikaela.malaczewski@ucdenver.edu
ESS-NSPAS Study 14-1808
Bayer HealthCare is sponsoring a medical research study to look at the effectiveness of Essure after having a procedure (NovaSure) that decreases your heavy menstrual bleeding. Both Essure and NovaSure are approved by the FDA. This study is enrolling patients now and you may qualify to participate.
Are you currently using the Essure method of contraception? Are your periods heavy, frequent or prolonged? One important prerequisite is - you must have had a successful Essure placement AND be willing to undergo a NovaSure endometrial ablation, a treatment option for heavy menstrual bleeding (menorrhagia).
PI: Tocce, Kristina
  • 303-724-5559
  • christina.gavito@ucdenver.edu
Volunteers Needed for Cardiovascular Research Study at the Division of Renal Diseases and Hypertension Clinical Research Unit 15-0869
This research study will compare blood vessel function in healthy adults to adults with two different types of kidney disease. The testing visit will include non-invasive testing of blood vessel function and collection of blood and cells from an IV.  As a volunteer, you will receive the following information about your health: resting EKG; blood cholesterol screening,    blood sugar screening, blood pressure screening, and physical Exam.
We are looking for men and women, aged 18-80 years, non-smokers, generally healthy, and free from hypertension. Women must not be pregnant of trying to become pregnant
PI: Nowak, Kristen
  • 303-724-9508
  • Heather.Farmer@ucdenver.edu
Volunteers are Invited for a Research Study Looking at Pain in Knee Osteoarthritis 12-1188
- To better understand the complex experience of pain for people with knee osteoarthritis - This study will measure different aspects of pain perception and knee function in people with and without knee osteoarthritis
- Age 50-85 - NOT diagnosed with knee osteoarthritis - NO knee pain
PI: Stevens-Lapsley, Jennifer
  • 303-724-9590
  • kneepain@ucdenver.edu
Do you have insomnia or Use cannabis to help you sleep? HS-2854
We are interested in learning more about the effects of cannabis use for insomnia and how it may or may not affect your sleep
Adults 21-80 years old cannabis use for sleep
PI: Bowler, Russ
  • 303-270-2462
  • MorrisM@NJHealth.org
Healthy Women Needed 15-1052
This study plans to research how metabolic challenges of increased insulin and increased fats affect reproductive hormones.
In order to be eligible you must: Be a healthy woman age 18-38, have a BMI between 18 and 25, have regular menstrual cycles (25-35 days), not be currently using hormones (like birth control medication), not be pregnant or planning to become pregnant. In order to enroll all participants must meet specific criteria. The criteria listed above is only a partial list of all the requirements. Only a clinical research staff member can determine eligibility.
PI: Santoro, Nanette
  • 303-724-5276
  • sarah.black@ucdenver.edu
Are you interested in learning about how your breast milk helps your baby grow? 12-0629
To find out how maternal size and diabetes status affect her breast milk To find out what unique parts of breast milk may affect how infants grow. To learn how to ensure infants receive the best nutrition possible
Women 20-35 who are at least 28 weeks into their pregnancy and planning on exclusively breastfeeding their infant for at least 4 months and delivering at University of Colorado Hospital.
PI: Krebs, Nancy
  • 303-724-3972
  • catherine.chartier-logan@ucdenver.edu
Free Family Therapy for Youth with Mood Problems 11-1048
Helping youth and their families understand and cope with mood swings, develop plans for preventing moods from getting worse, communicate more effectively and solve family problems
  • Youth between 9-17 who has recently had significant mood swings, has at least one parent with bipolar disorder and does not abuse alcohol or substances. 
  • Must agree not to participate in family therapy with another provider for the first year.
PI: Schneck, Christopher
  • 303-492-1668
  • Anna.Frye@colorado.edu
Genital Herpes? 13-2122
This study will look at the body's immune response (how the body fights infection) to the onset of genital herpes.  1-2 study visits for blood draws over the course of 3 months.
  • 18+ years of age
  • Have developed an outbreak of genital herpes within the last 10 days.
PI: Levin, Myron
  • 303-724-2454
  • nancy.lang@ucdenver.edu
Healthy Males needed for a research study of drug levels in blood and hair. 13-0427
This study plans to learn more about how tenofovir and emtricitabine (Truvada) build up in cells in blood and hair. Participation will include two 12 week dosing periods separated by a 12 week washout period (total duration is 36 weeks). Eligible participants will be given the supply of medications for the study.
  • Must be age 18 to 50 years
  • Must own smartphone
  • Subject has a minimum scalp hair length of 2 cm in the occipital region.
  • Have a low risk for HIV-1 infection
PI: Anderson, Peter
  • 303-724-8296
  • kayla.bushman@ucdenver.edu
The Role of Gut Bacteria in the Development of Type 1 Diabetes. 11-1144
The goal of the research is to better understand the role bacteria that live in the intestine in the development of type 1 diabetes
  • Patients diagnosed with type 1 diabetes in the last 6 months 
  • Subjects with islet autoantibodies 
  • Subjects who do not have islet antibodies and are first-degree relatives of patients with diabetes or subjects with islet antibodies
  • 1-45 years of age
PI: Zipris, Danny
  • 303-724-6820 or 303-724-6821
  • aimon.alkanani@ucdenver.edu or james.needell@ucdenver.edu
Are you interested in participating in a research study to help us learn more about where the fat tissue in your body originates? 13-0026
To understand if some fat cells (adipocytes) may originally come from cells in the bone marrow. Understanding the origin of fat cells is important because it may help to determine the health of fat cells and why fat that is stored in some places of your body is more ‘unhealthy’ than other fat.
Men and women: Between the ages of 18 and 75 years AND Had an allogeneic hematopoietic stem cell transplant at least 6 months ago –OR– Have chronic phase chronic myeloid leukemia.
PI: Klemm, Dwight
  • 303-724-7472
  • kathleen.gavin@ucdenver.edu
Are you looking for an alternative treatment for your insomnia? HS-2891
The purpose of this pilot study is to learn more about treatments for insomnia. Long-term use and dependence on controlled substance sleep medications (also known as “hypnotics”) is a common issue and is a less than ideal way to treat insomnia. Stopping the use of sleeping pills and trying other treatments for insomnia is difficult for many insomnia patients. Treatments combining supervised medication tapering (SMT), which is a gradual reduction of medication use, and cognitive behavioral insomnia therapy for insomnia (CBT-I), which is a form of talk therapy that helps a person learn to better handle behaviors, habits and thoughts that lead to sleeping problems., help some who wish to stop using sleep aids, but many individuals who complete these treatments do not give up their sleep aids altogether. This project will look at how to best help insomnia patients transitioning from using sleep aids to other treatment options for their insomnia.
• Adults 21 years of age and older who have chronic insomnia • Current medication use for treatment of chronic insomnia (over one year) • Desire to stop medication use
PI: Wamboldt, Fred
  • 303-270-2850
  • BurlesonA@NJHealth.org
Research Study Evaluating the Implementation of a Transdiagnostic Group Intervention for Children with Behavior Problems within a Pediatric Outpatient Setting 16-0275
Research study designed to learn more about a 10-week group therapy program that might be helpful for children with behavior problems and their parents/legal guardians.
Inclusion criteria for child participants: - Between 8-12 years old - Have behavior problems or a behavior disorder, such as Oppositional Defiant Disorder, Conduct Disorder, Attention-Deficit/Hyperactivity Disorder, Intermittent Explosive Disorder, Disruptive Mood Dysregulation Disorder - Able to read and complete English-language questionnaires - Able to attend 10 consecutive weeks of 90-minute group therapy sessions at Children’s Hospital Colorado - Have at least one parent/legal guardian able to complete English-language questionnaires and willing to participate in parent sessions. Exclusion criteria for child participants: - Intellectual disability - Developmental disability or significant developmental delay - Current suicidal ideation, homicidal ideation and/or self-harm behaviors - Active substance use problems - Current participation in psychological treatment or participation in psychological therapy within the past year - Do not have at least one parent/legal guardian willing to participate in the study
PI: Malmberg, Jessica
  • 720-777-4169
  • Laura.White@childrenscolorado.org
Help Us Generate Normal Laboratory Values 15-2091
Oxidative stress is increasingly recognized as being involved in disease processes. This research study will look at specific biomarkers of oxidative stress and levels of a natural antioxidant in healthy individuals. Several disease specific biomarkers will also be looked at. The data collected will be used to generate normal laboratory values in healthy individuals. the data generated will allow for evaluation of oxidative stress as a disease process in a rare metabolic disorder.
Are between ages of 8 and 50 years old Do not smoke Are not pregnant or nursing Do not take large doses of antioxidants such as vitamin C or vitamin E Are not ill with a disease that results in inflammation
PI: Van Hove, Johan
  • 720-777-4690
  • Michelle.Hite@childrenscolorado.org
Participants needed for a study with Diabetes and couples health behaviors 15-0601
This is a couples-based approach for increasing physical activity among adults with type 2 diabetes. Increasing physical activity has been shown to have great health benefits for managing diabetes.
One partner (or both) has Type 2 Diabetes One partner (or both) has been sedentary Each member is willing to increase their current level of physical activity Between the ages of 30 and 69
PI: Wooldridge, Jennalee
  • 720-372-3856
  • healthycoupleslab@gmail.com
Healthy men needed for cardiovascular study 15-1162
The purpose of this research is to study how low testosterone affects the health of the heart and arteries in men.
- Men 18-40 years or 50-70 years old, in general good health - No history of cancer, diabetes or heart disease - Non-smokers - Not currently taking medications to treat high blood pressure, cholesterol, taking testosterone therapy or exercising vigorously more than 2 days per week
PI: Moreau, Kerrie
  • (303) 724-2253
  • cardiovolt.study@ucdenver.edu
Are you at risk for type 2 diabetes ? 14-2402
Physicians at 23 sites across the United States are conducting a research study in adults at risk for diabetes to see whether daily vitamin D supplementation can delay the onset of diabetes. Understanding whether vitamin D has an effect on glucose (sugar) metabolism may lead to new treatments for diabetes. According to the Centers for Disease Control and Prevention, about 80 million people are at risk for developing diabetes. Persons who are older than 45 years of age, are overweight, have a family member with diabetes, have high blood pressure, or who do not get enough exercise are at risk for type 2 diabetes. Women who had diabetes during pregnancy and people from certain ethnicities are also at risk.
Men or women older than 30 years who are at risk for diabetes. You must agree not to take nutritional supplements or other preparations during the study containing vitamin D in excess of 1000 units per day or calcium in excess of 600 mg per day from all sources combined. Persons with diagnosed diabetes, kidney stones or kidney disease are not eligible. Other exclusions also apply.
PI: Rasouli, Neda
  • 720-848-7710
  • victoria.haggett@ucdenver.edu
Do you have Parkinson's Disease? 11-1237
To explore the effects of different doses of endurance exercise in people with PD.​
Persons 40-80 who have been diagnosed with Parkinson's Disease and are not yet taking medication or plant to start medication within the next 6 months. You must be willing to begin the exercise program immediately or after a delay of 6 months and willing to do aerobic exercise on a treadmill.
PI: Schenkman, Margaret
  • 720-848-6376
  • Toby.Wellington@ucdenver.edu
Do you have Atopic Dermatitis (Eczema)? HS-2581
To study eczema
Males and Females between 3 and 80 who have atopic dermatitis or males and females between 8 months and 80 who have a history of, or an active case of eczema hereticum (wide-spread herpes skin infection along with atopic dermatitis.
PI: Leung, Donald
  • 303-398-1409
  • taylorp@njhealth.org
Better Control of Type 2 Diabetes May Decrease Your Risk for Cardiovascular Disease. 10-0644
To look at the use of an extended release formula of Exenatide compared to a placebo to maintain normal glucose levels. Ultimately to see better control of diabetes and a decrease in cardiovascular disease events.​
Person 18+ with Type 2 Diabetes and take no more than 2 diabetes medications with stale doses for the last 3 months. Must not have a planned or anticipated revascularization procedure, but may have a history of cardiovascular disease and must see your primary care physician at least twice a year.
PI: Rasouli, Neda
  • 303-399-8020 X2059
  • chantal.underkofler@ucdenver.edu
Type 2 Diabetes and Exercise Research Study 10-1393
To research the effects of an investigational drug on exercise capacity and blood vessel function​.​
Person 30-60 with Type 2 diabetes who exercise vigorously less than one hour per week and have normal blood pressure. Must not have smoked for at least one year and have a BMI between 25-39.9.
PI: Schauer, Irene
  • 720-848-6690
  • Ellen.Lyon@ucdenver.edu
Are you a Non-smoking Adult between the ages of 45 and 85? HS-1883a
We are interested in learning more about smoking related lung disease, and need healthy non-smoking participants.
45-85 years old Non-Hispanic White or African American No smoking history No evidence of lung disease
PI: Bowler, Russ
  • 303-398-1772
  • SchnellC@NJHealth.org
Volunteers needed to Participate in a Research Study about Rheumatoid Arthritis 01-675
The purpose of this study is to learn more about how rheumatoid arthritis develops by studying people who do not have rheumatoid arthritis. Your participation in this study will help us determine if certain genetic and environmental factors affect the chances of developing RA-related autoantibodies in absence of rheumatoid arthritis.
You may be eligible to participate in the study if: -You are at least 40 years old -You do NOT have Rheumatoid Arthritis (RA)
PI: Norris, Jill
  • 303-724-7510
  • Marie.Feser@ucdenver.edu
Restoring Insulin Secretion (RISE) 13-0122
The Children’s Hospital Colorado Clinical Translational Research Center and the National Institutes of Health are conducting a study. This study is aimed at testing whether early treatment is beneficial to kids with early type 2 diabetes and kids at high risk of diabetes.
10-19 years of age, Pubertal, Overweight, Fasting glucose: >90 mg/dl; Impaired glucose tolerance: >140 mg/dl; Pre-diabetes or diagnosed with diabetes for less than 6 months; Metformin
PI: Nadeau, Kristen
  • 720-777-6143
  • susan.gross@childrenscolorado.edu
Do You Smoke? 12-0181
To figure out how these lung substances work in people who drink too much alcohol, who usually smoke, compared to those who do not drink heavily, but who smoke.
Smoking and nonsmoking males
PI: Burnham, Ellen
  • 303-724-6081
  • Carrie.Higgins@ucdenver.edu
Parents or Legal Guardians of Children with Disabilities 12-1664
Assistive Technology Partners, University of Colorado, Anschutz Medical Campus, is performing a study investigating the impact Socially Assistive Robotics has on motor, communication and cognitive skills of children with disabilities.
Children between the ages of 18 months to 5 years of age Have Significant motor and communication disabilities/delays NOT been diagnosed with blindness or deafness They are without a seizure disorder or with a well-controlled seizure disorder They have been on stable medication regime for the past 12 weeks, if they are currently taking medication.
PI: Sandstrum, Jim
  • 303-315-1287
  • Jim.Sandstrum@ucdenver.edu
The Influence of Couples' Conversation on the Heart 13-2188
The purpose of the study is to examine the influence that conversations between married couples have on the functioning of the heart.
Married Christian couples who: • Have been married for at least 1 yr. • Both believe in prayer. • Are not currently taking heart medications. • Do not have heart problems. • Are not pregnant.
PI: Grigsby, Megan
  • 303-556-6020
  • couplesandheartstudy@gmail.com
Help Us Learn About Schizophrenia! 12-1186
Help us learn more about a new drug that may improve thinking and concentration in people with schizophrenia.
We are looking for: Male and female adults who smoke 18-50 years old No previous or current mental illness No drug use Willing to use nicotine patch during study hospital visit If female, willing to use birth control during the study
PI: Freedman, Robert
  • 303-724-6214 or 303-724-7373
  • psypharmresearch@ucdenver.edu
Research Trial Evaluating a New Drug in Psoriasis: Now Enrolling 14-1692
The study will evaluate an investigational drug compared to a currently approved psoriasis medication. Your participation will provide valuable information to researchers seeking new and improved therapies. You will be given either Humira, placebo, or the investigational drug for up to 28 weeks, after which you may be switched over to the active drug depending on your response.
You may be eligible to participate if 18 years of age or older and have been diagnosed with moderate to severe plaque-type psoriasis for at least 6 months.
PI: Alkousakis, Theodore
  • 720-848-0556
  • psoriasiscolorado@ucdenver.edu
Exercise for Healthy Aging 14-2207
To determine whether a high versus a moderate intensity of cardiovascular + strength training has a greater improvement on health and quality of life.
Eligibility: Men aged 50-68, no major health problems that would interfere with the ability to exercise; if diabetic, must be well-controlled on oral medications (no insulin); body mass index between 20 and 40; no current/chronic infections.
PI: Erlandson, MD, Kristine
  • 303-724-4941
  • kristine.erlandson@ucdenver.edu
Do you have high blood pressure? 13-3174
Study to help predict if blood pressure medications will work for you.
You may be eligible if you are an adult aged 30-80 with a diagnosis of uncontrolled essential hypertension. You must not have a history of end stage liver or renal disease, cannot be pregnant, and cannot be allergic to metoprolol.
PI: Monte, Andrew
  • 303-724-7871
  • Glenn.McWilliams@ucdenver.edu
Give Us a Hand 12-1084
To better understand Multiple Sclerosis in children and teens.
Between the ages of 3-20 AND have Multiple Sclerosis diagnosed before 18 OR Do not have MS
PI: Schreiner, Teri
  • 303-724-3635
  • Ildiko.Torok@ucdenver.edu
Are you an African American with asthma? HS-2805
 We are studying why some African American people have trouble with their asthma despite taking asthma medications.
 Children age 5-17 and non-smoking Adults age18 and older who have asthma symptoms despite asthma treatment • African American ancestry (have at least one    African American grandparent)
PI: Wechsler, MD, Michael
  • 303-398-1443
  • sundstromd@njhealth.org
Peanut and Tree-Nut Allergy Research Study 13-2102
The purpose of this study is to determine how the body's immune system interacts with nuts and other foods to cause allergic reaction.
6-75 years of age.  Have a diagnosis of peanut and/or tree-nut allergy made by either skin test or blood tests.
PI: Dreskin, Stephen
  • 303-724-7193
  • Spodra.Eglite@ucdenver.edu
Do you have human growth hormone (hGH) deficiency? 13-2629
Primary: To demonstrate a clinical superiority of MOD-4023 over placebo in terms of decrease in Fat Mass (FM) in adult subjects with Growth Hormone Deficiency Secondary a. To determine the efficacy of MOD-4023 over placebo in other body composition variables (such as lean body mass and waist-to-hip ratio) b. To evaluate the safety and tolerability of MOD-4023 over placebo in adult subjects with GHD c. To determine the IGF-I and IGFBP-3 serum levels
Adult men and women aged 23 to 70 years of age diagnosed with either adult or childhood onset growth hormone deficiency (GHD).
PI: Wierman, Margaret
  • 720-848-7710
  • Shannon.Moore@ucdenver.edu
Are you a parent of a child with a developmental disability and willing to contribute to a research project to increase awareness and understanding? 14-1287
The purpose of this study is to gain knowledge on the topic of everyday stressors that affect the lives of children with developmental disabilities, as well as their parents/caregivers
Are you a parent of a child with a developmental disability and willing to contribute to a research project to increase awareness and understanding?
PI: Benson, Brenna
  • 303-520-7346
  • brenna.benson@ucdenver.edu
Healthy Female Adults Needed!!! 07-0816
For brain imaging research study on how the brain works with we taste sweets. Your participation could help us to develop treatments and preventive measures for anorexia nervosa and obesity
Healthy females 22 to 29 who are right-handed, free of medication with no serious medical conditions, permanent metal implants or braces/retainers, and are at a healthy body weight.
PI: Frank, Guido
  • 720-777-4026
  • imaging.research@childrenscolorado.org
Do you have an egg allergy? HS-2764
To see if taking Baked Egg Therapy vs. Oral Immunotherapy may help egg-allergic children tolerate eggs.
males and females 3 to 16 years old, with documented egg allergy, ability to make regular visits to National Jewish Health for up to 2 years.
PI: Leung, Donald
  • 303-398-1618
  • ReamesR@NJHealth.org
Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) 15-0023
Pitavastatin is a statin that along with diet is used for the treatment of high cholesterol. It also lowers triglyceride levels in the blood. The main purpose of this clinical trial is to see if pitavastatin can prevent heart disease and heart disease related deaths in people with HIV infection who are taking HIV medications.
This study lasts about 6 years (21 visits) and you may be eligible if: • You have HIV and are between the ages of 40 and 75. • You have been on antiretroviral therapy (ART) for at least 6 months. • You have a CD4+ cell count > 100. • You have no history of cardiovascular disease (history of heart attack or stroke, etc.). • You are not currently using a statin drug.
PI: Campbell, MD, Thomas
  • 303-724-0712
  • graham.ray@ucdenver.edu
Paid Volunteers Needed for high blood pressure study PR2015-149
Looking for participants in clinical studies. Tests conducted to evaluate Blood Pressure devices per FDA requirements.
Subjects must be 3 years of age and have an arm circumference between 12-55cm.  Looking for healthy Adults, and Kids, non-medicated High Blood Pressure, and individuals with large arms/biceps.  Studies conducted year round on an on-going basis. Payment made on a per study basis, typical $50-100/study.
 
PI: Ransom, David
  • 303-884-2499
  • AFedorRN@clinimark.com
Are You a Healthy Individual Looking to Help With Research 09-0816
This is a research study to learn more about the risk factors, features, and treatment or prevention efforts for bleeding disorders.
Aged 1 to 17 Healthy
PI: Manco-Johnson, Marilyn
  • 303-724-3856
  • taylor.blades@ucdenver.edu
Are you interested in participating in a research study to help us learn more about where the fat tissue in your body originates? MYTH Study 15-1779
This research study plans to learn more about where the fat cells in your body come from.  Understanding the origin of fat cells is important because it may help to determine the health of fat cells and why fat that is stored in some places of your body is more "unhealthy" than other fat.
We are enrolling men and women who are: Age 21-40 y or 55-85 y; BMI 22-35 kg/m2; Weight stable (not actively gaining or trying to lose weight); Non-active to moderately active (exercise ≤ 3 days/wk lasting < 30 min); Not taking any hormonal therapy (testosterone, estrogen/progesterone replacement, or hormonal contraceptives); Not diagnosed with type 2 diabetes or taking glucose or lipid lowering medication; Not pregnant or planning to become pregnant in the next month
PI: Gavin, Kathleen
  • 303-724-7472
  • kathleen.gavin@ucdenver.edu
Healthy Volunteers Needed for a Drug-Drug Interaction Research Study 15-0106
The study will look at the levels of dolutegravir (a HIV medication) and simeprevir (a Hepatitis C medication) in the blood when given alone and in combination.
We are looking for men and women who are: -HIV and Hepatitis C negative -Age 18-60 -Do not have chronic health conditions requiring medications, including but not limited to, high blood pressure, diabetes, eczema, or psoriasis -Not taking any medications except aspirin, Tylenol, ibuprofen, or oral contraceptives
PI: Kiser, Jennifer
  • 303-724-5564
  • ryan.huntley@ucdenver.edu
Research study on the effects of an investigational drug on weight and neuronal response 15-0650
This research study plans to examine the effects of an investigational new drug on neuronal, physiological, and behavioral mechanisms of obesity in the general population.
To be eligible for the study, participants must have a BMI greater than 27 kg/m2, be 21-65 years old, be a non-smoker, have no known cardiovascular disease, have no significant endocrine/metabolic disease, must not be pregnant or trying to conceive, and must be able to complete an MRI scan.
PI: Tregellas, Jason
  • 303-724-8299
  • brainstudy@ucdenver.edu
Participants Needed for Web--Based Research Study 16-0738
The purpose of this research is to learn about the quality and quantity of specific healthcare information that is available to healthcare consumers on the internet, and the ease by which such information is available to healthcare consumers
Adults aged 18 years old and over who do not have a professional background in medicine or medical research, and who are not currently considering hospice enrollment for themselves or someone else. Participants must be able to find transportation to the Anschutz Medical Campus for the purpose of the study and be able to use a computer for the purpose of online information searching.
PI: Allen, Larry
  • 303-724-9647
  • grace.finnigan-fox@ucdenver.edu
If you child suffers from rashes or skin allergies he or she may qualify to take part in a research study. 12-1208
To test seven new antigens on the child and adolescent population to add to the current standard test
Children and adolescents 6-17 diagnosed with contact dermatitis or may have contact dermatitis who are willing to wear test patches for 2 days and are available for follow-up visits
PI: Dunnick, Cory
  • 303-724-9155
  • Teresa.Derian@ucdenver.edu
Investigations in Gestational Origins of Lifetime Development: Understanding health begins before birth. Are you in your first trimester of Pregnancy? 07-0535
To learn more about how your metabolism is connected to your baby's growth and development
  • Healthy Women ages 18-35 who are 10-14 weeks pregnant with single baby.  With a  BMI of 30-38 who are willing to complete 5 visits during pregnancy and agreeable to an infant blood draw at birth and DXA postpartum.  
There is an option to take part in a 1 year follow-up which entails an additional 4 visits and another DXA at 1 year of life.
PI: Barbour, Linda
  • 303-724-3974
  • catherine.chartier-logan@ucdenver.edu
We are Currently Enrolling People with Down syndrome for a study in Dr. Pelak's Brain and Vision Research lab at the University of Colorado Anschutz Medical Campus. 05-1131
To examine visual brain function in people with mild memory impairments to detect early signs of Alzheimer's Disease.​
Persons 19-30 who have Down Syndrome
PI: Pelak, Victoria
  • 303-724-2184
  • Jerri.Lusk@ucdenver.edu
EMERALD STUDY: Effects of MEtformin on CardiovasculaR function in AdoLescents with Type 1 Diabetes 12-1528
​To determine the effects of Metformin on Cardiovascular Function in Adolescents with Type 1 Diabetes.
  • Persons 12-21 who have Type 1 Diabetes
  • Non-smoker, able to ride a stationary bike
  • You must be willing to take metformin or placebo (sugar pill) for 3 months.
  • Other exclusions apply, please contract study for more information
PI: Nadeau, Kristen
  • 720-777-5774 or 720-777-6143
  • susan.gross@childrenscolorado.oramy.baumgartner@childrenscolorado.org
Non-Alcoholic Fatty Liver Disease and Obstructive Sleep Apnea: Mechanistic Links between Hypoxemia and Liver Injury 09-0169
To learn if obstructive sleep apnea and low oxygen levels have a role in developing Non-Alcoholic Fatty Liver Disease (NAFLD).​​​
Children 10-17 who have a normal weight and no serious medical problems
PI: Sundaram, Shikha
  • 720-777-3819
  • Kristen.robbins@childrenscolorado.org
Exercise and Cancer Prevention Research Study 13-2314
The goal of this study is to better understand the biological mechanisms associated with exercise and reduced risk for breast cancer.
  • You must be a female between the ages of 30-45 to participate in this study. 
  • You must be planning to live in the Denver metropolitan area for the next 10 consecutive months. 
  • You should not be a regular exerciser because this study is for people who do not exercise right now; however, you should be willing to participate in an exercise program 4 times per week for 16-weeks.
PI: Bryan, Angela
  • 303-492-9549
  • cuchange@colorado.edu
Are you interested in a supervised exercise intervention? 13-3252
Volunteers are needed for a research study to examine the effects of exercise on food intake and appetite regulation.
  • 21-45 years old
  • Non- smoker
  • Non- Diabetic
  • Exercise no more than 1 time a week
  • Maintained your current weight for last 6 months
  • Have a body mass index (BMI) of 27-35 (check it out at http://nhlbisupport.com/bmi/)
PI: Cornier, Marc
  • 303-724-9024
  • allison.hild@ucdenver.edu
Study of Mood Disorder in Preschool Children 07-0932
We are doing a research study to better understand what mood disorders look like in preschool children.
We are looking for volunteers who:  
  • Are parents of children between the ages of 4 and 6 years 0 months.
  • Are in one of three groups:
    1. Their child has no major mental health problems, and there is no family history of major mood or psychotic disorders.
    2. Their child has been diagnosed with a mood disorder, bipolar disorder, or mood dysregulation disorder. 
    3. Their child has been diagnosed with attention deficit hyperactivity  disorder (ADHD).  
  • Parents or guardians will be asked to:
    • Read and sign a consent form
    • Participate in interviews about their children
  • The  children will be asked to:
    • Participate in a story game
    • Take tests of verbal and nonverbal abilities
How much time will this take?
The visit for the child will last from 1 to 2 hours.  The visit for the parents will last 3 to 5 hours.
PI: Ross, Randy
  • 303-724-6200
  • Kate.Noonan@ucdenver.edu
Understanding how Tysabri and Gilenya Influence the Quality of your Daily Life with Multiple Sclerosis 13-2767
The purpose of this research study is to compare two medications, Tysabri and Gilenya, used in the treatment of multiple sclerosis (MS), through a few self-reported patient surveys. We will ask you to complete online surveys about overall health-related quality of life, disability, fatigue, cognition and productivity. We will also want to review your medical records to understand your MS history with your permission. This study will help us understand how these drugs are impacting each aspect of your daily lives.
  • Between ages 16 and 65
  • Scheduled to start natalizumab or fingolimod for the first time to treat your MS
PI: Nair, Kavita
  • 303-724-8388
  • Eric.Engebretson@ucdenver.edu
Living with MS? 12-1522
To evaluate the safety of a new investigational drug that may help reduce relapses.
  • Between the ages of 18 to 65
  • Participants must have relapsing-remitting multiple sclerosis (RRMS)
PI: Corboy, John
  • 303-724-7421
  • Kristina.Bliss@ucdenver.edu
Are you Pregnant or a Nursing Mother? Consider being a part f a Breast Cancer Research. 12-0769
This study will examine changes that occur in the breast tissue, blood and urine of a woman after she has given birth to a child. The study will examine how a woman’s breast and her cells change after pregnancy and breast feeding and how her immune system interacts with these changes. The immune system is a complex network of cells that identify our tissues as “self” or “foreign” as well as normal cells or cancer cells. We hope to discover how a woman’s breast changes after pregnancy or breast feeding to see if this time point in a woman’s life could be targeted to prevent breast cancer.
You are being asked to be in this research study because you are pregnant or were recently pregnant and have not had breast cancer or another autoimmune disease.
PI: Borges, Virginia
  • 303-724-6077
  • emily.rozzo@ucdenver.edu
Do You have type 1 diabetes? 14-2423
To learn more about an investigation study drug
    • Persons 18 to 30 years who have had Type 1 Diabetes for 12 months
    • Have a stable insulin treatment (MDI or pump) 3 months and an A1C 9.0
    • Not using an antidiabetic agent other than insulin or insulin analogue
    • Willing to take study drug or placebo pills daily for 3 months
    • Not pregnant, breast-feeding or intending to become pregnant
    • Other inclusion/exclusions apply, please contact study coordinator for more information
 
PI: Paul R, Wadwa
  • 303-724-9267
  • cierra.sullivan@ucdenver.edu
Will You Be a Caregiver For Your Loved One During Transplant? 13-2639
We are conducting a research study to assess treatments to reduce the effects of stress on caregivers of patients experiencing an allogeneic transplant.
Patient inclusion criteria include: 1) receiving an allogeneic HSCT, 2) able to read and speak English, 3) telephone access. Caregiver inclusion criteria include: 1) the person in the patient's life who is primarily responsible for care decisions, emotionally invested in the patient's care, provides instrumental care such as transportation, and available if randomized to the fPER group to participate in the majority of intervention sessions, 2) able to read and speak English, 3) willingness to use a Smartphone, 4) absence of a serious medical condition likely to influence hair cortisol, 5) no steroid medications, and 6) over the age of 18 years.
PI: Laudenslager, Mark
  • 303-724-9279
  • Carewell@ucdenver.edu
DO YOU HAVE GESTATIONAL DIABETES? Would you like help with your GDM Diet? 14-1358
Research Subjects Needed to Participate in a Diet Research Study in Women with Gestational Diabetes
Who can qualify? * Highly motivated pregnant women with Gestational Diabetes not taking medicine for blood sugar control * Women willing to follow 1 of 2 healthy diets for blood sugar control * Women willing to complete 6 visits during pregnancy with infant follow up * Gestational age: <31 weeks; singleton pregnancy * Healthy  women, age : 20-36 years * No high blood pressure * Overweight or Obese
PI: Hernandez, Teri
  • 303-724-3974
  • catherine.chartier-logan@ucdenver.edu
Volunteers needed for a NASH therapeutic trial 14-2108
Clinical research study of an investigational product for the treatment of non-alcoholic steatohepatitis (NASH)
*≥18 years old *Confirmed diagnosis of NASH *No other liver disease *No excessive alcohol use (no more than 2 drinks/day for women and 3 drinks/day for men)
PI: Bambha, Kiran
  • 303-724-1871
  • colin.jenks@ucdenver.edu
We are looking for Healthy Men and Women to participate in the WATCH CALORIE Research Study 15-1570
The study will examine how diet impacts circadian clocks in abdominal fat tissue
Healthy women aged 20 to 35 years A BMI between 25- 30 Exercise less than 4 days per week Have a regular sleep schedule
PI: Rynders, Corey
  • 720-848-6461
  • corey.rynders@ucdenver.edu
Study of Pre and Postnatal Infant Brain Growth and Development 15-0707
Through a study of infants before and after pregnancy, researchers at Children's Hospital Colorado and the University of Colorado Denver will investigate the impact of mother and infant nutritional health on infants' cognitive development.
* That mom (you) was at least 18 when you had your child. * Delivered full term (at least 37 weeks).  * English speaking (as one of the household languages). * Your child was part of a singleton pregnancy.  * No abnormalities found on the fetal ultrasound and no serious complications during delivery.  * No smoking, drinking, recreational drug use or prescription drug abuse during pregnancy. * No diabetes before or during the pregnancy.  * No high blood pressure before or during the pregnancy.  * No metal in or on your child’s body that would make it unsafe for him/her to have an MRI scan. 
PI: Deoni, Sean
  • 720-777-8756
  • info@childimaginglab.org
Heavy periods affecting your life? You have options. 16-0571
The purpose of this study is to better understand the causes of heavy menstrual bleeding and to identify women who are suitable candidates for an endometrial ablation procedure. Endometrial ablation is a procedure designed to reduce or even stop menstrual bleeding.
a. Between 25-50 years of age b. Heavy menstrual bleeding c. Have not given birth in the last 6 months, are not currently pregnant, and do not wish to become pregnant in the future.
PI: Tocce, Kristina
  • 7205051710
  • shara.evans@ucdenver.edu
Help Us Learn More about Care Decisions at End-of-Life . . . A Hospice Decision-Making Research Project 16-0479
The goal of this project is to conduct a needs assessment to learn what information patients, providers and informal caregivers think should be included in hospice decisional support materials.
-Cared for a loved one with advanced illness -Have lots of illnesses or advanced illness? -Have you or a loved one considered hospice -Are you willing to participate in a focus group and/or personal interview to share your experiences and opinions about major decisions near the end of life? OR -Are a doctor, nurse, social worker, clergy member or another professional that works with seriously ill patients -Do you volunteer with hospice or with patients making end-of-life care decisions? -Do you have experience with referring patients to hospice? -Do you have experience caring for patients in hospice? -Do you have experience caring for patients near death? -Are you willing to participate in a focus group and/or personal interview to share your experiences and opinions about major decisions near the end of life?
PI: Matlock, Dan
  • 303-724-8985
  • channing.tate@ucdenver.edu
Type 2 Diabetes and Exercise Research Study 11-0909
Perceived exertion during exercise
Person 50-70 with or without Type 2 diabetes who exercise vigorously less than one hour per week and have normal blood pressure.  You should have a BMI between 25-35 and have not smoked for a least one year.
PI: Huebschmann, Amy
  • 303-724-2255
  • Ian.Leavitt@ucdenver.edu
Participants Ages 12-15 years old Needed for Research Study 04-0311
To learn about how children with absence epilepsy compare to healthy children in areas such as behavior, neuropsychological skills and quality of life.
Healthy hispanic individuals who are 12-15 years; No history of seizures, seizure like episodes, neurological diseases or a loss of consciousness greater than 5 minutes in their immediate family
PI: Levisohn, Paul
  • 720-777-8608
  • Nanastasia.Welnick@childrenscolorado.org
MRI and Questionnaire Research Study for Patients with MS Taking Tysabri and Healthy Controls 13-2927
This research study plans to learn more about the differences in brain scans and self-reported quality of life between MS patients taking natalizumab (Tysabri) and individuals without MS.
A relapsing Multiple Sclerosis patient 18-55 years old who has been taking Tysabri (natalizumab) for at least 2 years

OR

A healthy individual 18-55 years old without Multiple Sclerosis or other neurological conditions
PI: Miravalle, Augusto
  • 303-724-8388
  • Eric.Engebretson@ucdenver.edu
Participants Needed for an Exercise Study for People with Multiple Sclerosis 14-0295
Researchers from the Neurophysiology of Movement Laboratory on the University of Colorado Boulder campus and the Multiple Sclerosis Center on the University of Colorado Anschutz Medical Campus are conducting a study to investigate the capacity of neuromuscular electrical stimulation to improve walking in persons with multiple sclerosis.
-Between 18 to 55 years of age -Have clinically confirmed diagnosis of MS -Are able to talk but have some difficulty walking
PI: Enoka, Roger
  • 303-724-4644
  • Roger.Enoka@colorado.edu
Healthy Adolescents Needed 07-0709
Psychological study on how flexible your brain can shift from one task to another.
-Female -age 12-17 years old -in good health -on no medication
PI: Frank, Guido
  • 720-777-4026
  • imaging.research@childrenscolorado.org
Help test a mobile app for postpartum moms 14-1173
This research study will test a mobile application to learn more about how to best deliver information about diet and physical activity for postpartum women at elevated risk for diabetes and heart disease.
You may qualify for this study if you:  Are between 18-45 years old  Are in your third trimester of pregnancy or have given birth in the last 24 weeks  Have a postpartum BMI: 25-45 kg/m2  Have access to and be willing to use a wi-fi enabled iPhone or an iPod  Have a history of one or more of the following complications in your most recent pregnancy: o Gestational diabetes mellitus o Preeclampsia o Gestational hypertension o Pre-term delivery (32-37) weeks o Small for gestational age (
PI: Nicklas , Jacinda
  • 303-724-8898
  • jessica.jaramillo@ucdenver.edu
Healthy Individuals needed for Genetic Study of Granulomatous Interstitial Lung Disease. HS-2765
To investigate genetic factors associated with the disease sarcoidosis.
Must be 18 years or older with no history of chronic lung disease (including asthma) or connective tissue/rheumatological disease. Participants must complete a questionnaire and have a small blood draw.
PI: Maier, Lisa
  • 303-270-2867
  • schrocks@njhealth.org
We are seeking physically active women and men for a research study on PTH and Calcium Responses to Exercise (PACE) in Older Adults 15-0250
To determine 1) if sweating rate during exercise affects the decrease in blood calcium level, and 2) if this causes an increase in a hormone called parathyroid hormone or PTH that causes bone to release calcium.
 A 60-80-year-old woman or man in generally good health  Often walk for exercise and can walk for an hour at a time  Not taking osteoporosis medication  No history of Diabetes or Cardiovascular Disease
PI: Wherry, Sarah
  • 720-848-6376
  • toby.wellington@ucdenver.edu
Are you interested in trying inhaled insulin for your meal/correction doses? 15-1112
The purpose of this study is to evaluate the blood levels of the study medication (Afrezza®), for blood sugar levels and safety after 4 weeks of treatment in children and adolescents between 4-17 years of age with T1DM
Age 4-17 years Type 1 Diabetes for at least 1 year A1C between 7-10% Stable Insulin doses for the past 6 weeks
PI: Wadwa, R. Paul
  • 303-724-8095
  • bao-khanh.tran@ucdenver.edu
Social Networks of Abused Prescription Pills in Youth (SNAPPY) Research Study 15-0504
The purpose of this research study is to learn more about the misuse of prescription pills and the risk for injection drug use.
You may be selected to participate in the study if you are: • Between the ages of 15 and 24 • Willing to provide information about people in your life and things you do with them • Currently using prescription opioids without a doctor’s prescription or in ways other than what was prescribed OR • Currently using heroin after a period of misusing prescription opioids
PI: Al-Tayyib, Alia
  • 1-888-897-3224
  • Alia.AlTayyib@dhha.org
We are seeking physically active men for a research study on PTH and Calcium Responses to Exercise (PACE) 12-0767
This study will determine how much calcium enters and leaves the blood during exercise.  The results of this study will help us find out why some adults who exercise a lot sometimes have low bone density
• Men in generally good health, aged 18-45 years • Regularly cycle for exercise and can ride for an hour at a vigorous intensity • Not taking medication for osteoporosis • No history of asthma
PI: Kohrt, Wendy
  • 720-848-6376
  • toby.wellington@ucdenver.edu
We are looking for adolescents who have received a solid organ transplant for a telehealth group research study! 13-2997
Learning how to improve adherence in adolescents who have received solid organ transplants and determining whether telehealth can be used to facilitate groups for teenage transplant recipients.
Teens between the ages of 13 and 17 who have received a heart, liver, or kidney transplant.
PI: Buchanan, Cindy
  • 720-777-5529
  • cindy.buchanan@childrenscolorado.org
Women with Obesity Needed! 07-0816
For brain imaging research study on how the brain works with we taste sweets. Your participation could help us to develop treatments and preventive measures for anorexia nervosa and obesity
Females 18 to 25 years old who are right-handed, currently overweight, have a body mass index (BMI) over 30, and no permanent implants or braces
PI: Frank, Guido
  • 720-777-4026
  • imaging.research@childrenscolorado.org
A Study to Evaluate Dolutegravir plus Lamivudine Dual Therapy for the Treatment of Naive HIV-1-Infected Participants 15-1624
The main purpose of this study is to evaluate how well a two-drug combination of study drugs (dolutegravir plus lamivudine) will suppress HIV at 24 weeks after starting treatment. The study will also look at the safety and tolerability of this study drug combination, and factors that may affect how well it works in different individuals.
-HIV-1 infected men and women at least 18 years of age -Have not taken HIV medications (except for successful prevention of HIV infection) -No evidence of resistance to the type of anti-HIV drugs being used in the study -Have blood HIV level (viral load) of at least 1000 copies/mL but less than 500,000 copies/mL -No active Hepatitis B infection
PI: Campbell, MD, Thomas
  • 303-724-0712
  • graham.ray@ucdenver.edu
Participants needed for a Balance and Fall-Risk Research Study for People with Multiple Sclerosis 15-1806
This study involves balance and head movement testing aimed at predicting risk of falls
Are between the ages of 30 and 60 years
• have MS
• are able to turn your head at least 30 degrees to the left,
• have not experienced a fall in the last 3 months
PI: Hebert, Jeffrey
  • 303-724-4717
  • molly.strobel@ucdenver.edu
Volunteers Needed for a Research Study about Rheumatoid Arthritis 14-1751
The purpose of this study is to learn more about how rheumatoid arthritis develops in women by studying women who do not have rheumatoid arthritis. Your participation in this study will help us determine if certain hormone or environmental factors affect the chances of developing protein markers associated with rheumatoid arthritis.
• You are a woman at least 18 years old • You do NOT have rheumatoid arthritis (RA)
PI: Demoruelle, Kristen
  • (303) 724-8319 or (303) 724-8330
  • Courtney.2.Anderson@ucdenver.edu
Do you like food? 13-1786
Participants needed for a study on foods Participants in this study will: - Rate a series of food pictures - Watch pictures of food during fMRI recording, to measure brain responses to the pictures - Complete an fMRI task with images shown briefly before food pictures. - May also eat a buffet-style breakfast and lunch. - Be compensated for their time (between 2-6 hours)
- Adults between 15-65 years old - BMI > 25
PI: Legget, Kristina
  • 303-724-8502
  • Brainstudy@ucdenver.edu
Healthy Women Needed 15-0474
To understand how weight affects reproductive health and fertility potential
In order to be eligible you must: Be a healthy women age 21-39 with BMI between 18.5 and 24.9 or greater than 30 Have regular menstrual cycles (25-40 days) Not currently using hormones (like birth control medication) Be willing to have frequent blood samples drawn In order to enroll all participants must meet specific criteria. The criteria listed above is only a partial list of all the requirements. Only a clinical research staff member can determine eligibility.
PI: Polotsky, MD MS, Alex
  • 303-724-9643
  • michelle.sheehy@ucdenver.edu
We are looking for adolescents who struggle with worries. 15-1593
Children’s Hospital Colorado is conducting a study of worry in adolescents, and looking at how particular thinking skills, and patterns of brain activity, might contribute to worry.
Adolescents may be eligible if they: 1) are between 13 and 18 years old; 2) do not have braces or other metallic items on their body that are not easily removed.  Participating adolescents will complete two study visits at Children’s Hospital Colorado, accompanied by a parent. At the second visit, they will have their brains scanned in a magnetic resonance imaging (MRI) machine on the Anschutz Medical campus.
PI: Mullin, Benjamin
  • 720-777-5086
  • emmaly.owens@ucdenver.edu
HEALTHY WOMEN NEEDED 15-0474
To understand reproduction hormones and fertility potential. To understand how weight affects reproductive health and fertility potential
Be a healthy women age 21-39 with BMI between 18.5 and 24.9 or greater than 30  Have regular menstrual cycles (25-40 days)  Not currently using hormones (like birth control medication)  Be willing to have frequent blood samples drawn
PI: Polotsky, Alex
  • 303-724-5276
  • anahit.malkhasyan@ucdenver.edu
MS Volunteers Needed for Research Study 12-1388
Looking to see if there is a cognitive improvement with the treatment of oral estriol as compared to oral placebo
We are looking for: • Women 18-50 years old • Diagnosed with definite relapsing-remitting, secondary-progressive multiple sclerosis or primary-progressive multiple sclerosis • MS disease duration of 15 years or less • On stable dose of standard MS treatment with Copaxone®, Betaseron® (or Extavia®), Rebif®,Avonex®, Gilenya®, Aubagio®, Tecfidera®, or no treatment ----You are not eligible for the study if you are pregnant, breast-feeding, smoke, or have other serious medical conditions.
PI: Corboy, John
  • 303-724-6351
  • Nicola.Haakonsen@ucdenver.edu
JUST DIAGNOSED WITH SHINGLES? 13-2122
This study will look at the body's immune response (how the body fights infection) to the onset of shingles. 1-2 study visits for blood draws, over the course of 3 months.
18+ years of age; NO PRIOR HISTORY of shingles; have NEVER received the shingles vaccine; have DEVELOPED SHINGLES within the last 10 days.
PI: Levin, Myron
  • 303-724-2454
  • nancy.lang@ucdenver.edu
protein and infant growth: Do you have a child younger than 6 months 14-0139
Participants in this research study on protein from complementary foods (meat or dairy) and infant growth, will learn how protein consumption affects your child’s growth, fat gain, and gut health from 6 to 12 months of age.  
To qualify, you child needs to be: 1. Formula fed, or not on breast-milk longer than 1 month. 2. Younger than 6 months. 3. Generally healthy. You will receive commercially available complementary foods for 7 months, Receive infant formula at no cost for 7 months, You will know your child's body fat and fat free mass and blood lipid level.
PI: Krebs, Nancy
  • 303-724-3248
  • minghua.tang@ucdenver.edu
HAVE YOU OR YOUR CHILD BEEN DIAGNOSED WITH ASTHMA? HS-2827
We are looking for volunteers to participate in an N.I.H. funded research study.
Children 12 years of age and older and non-smoking Adults who have mild to moderate asthma who are not currently taking inhaled steroid medication
PI: Martin, Richard
  • 303-398-1443
  • stevensa@njhealth.org
Do You or Someone You Know Suffer From Relapse Remitting Multiple Sclerosis (RRMS)? 13-2209
The University of Colorado Denver is conducting a clinical trial to evaluate the effectiveness, safety and tolerability of two doses of oral administration of laquinimod in subjects with Relapse Remitting Multiple Sclerosis (RRMS). Patients that suffer from RRMS may experience a gradual increase of their disability over time. The purpose of this study is to find out whether laquinimod is safe and effective in slowing the rate of disability progression.
-Between the ages of 18 and 55 -Have clinically confirmed diagnosis of Multiple Sclerosis (MS) with relapse onset disease or relapsing-remitting disease course -Have had at least one documented relapse within 12 months prior to starting this study -Have not been treated with Natalizumab (Tysabri) or Rituximab 2 years prior to starting this study
PI: Vollmer, Timothy
  • 303-724-6351
  • Nicola.Haakonsen@ucdenver.edu
Sedentary Behavior Research Study 14-0429
This research study plans to learn more about how the time we spend seated affects your health
Healthy male and female Age: 19-45 With BMI: 27-33 you may check this at: http://nhlbisupport.com/bmi/ Be seated more than 6hr/d Be physically active on less than 3-4 days/wk
PI: Bergouignan, Audrey
  • 303-724-9026
  • nathan.dejong@ucdenver.edu
Healthy Minority Volunteers Needed 13-0427
This study plans to learn more about how tenofovir and emtricitabine (Truvada) build up in cells in blood and hair. Participation will include two 12 week dosing periods separated by a 12 week washout period (total duration is 36 weeks). Eligible participants will be given the supply of medications for the study.
Documented negative testing for HIV and hepatitis B Not at risk for HIV Study population balanced by Caucasian, African-American, Hispanic race. African American and Hispanic participants are currently needed. Age 18-50 years Able to meet study personnel on Anschutz Medical Campus for directly observed dosing with study medication, or by audio-visual communication with a mobile cellular device when off Campus
PI: Anderson, Peter
  • 303-724-8296
  • Kayla.bushman@ucdenver.edu
Participate in a research study about body image dissatisfaction and psychosocial distress among breast cancer patients 15-0004
The purpose of this research study is to 1) determine the feasibility and impact of a 2 day body image workshop on breast cancer patients’ body image dissatisfaction, depression, and quality of life and 2) understand the relationships between body image, quality of life, and depression among patients with breast cancer.
Participants must be: 1) between the ages of 18-65, 2) histological or cytological confirmation of breast cancer (any clinical stage is allowed); 3) within 6 months of completion of surgery or final chemotherapy/radiation treatment for breast cancer, 4) experiencing concerns specific to body image.
PI: Pearson-Mauro , Adria
  • 720-251-4803
  • cubodyimage@gmail.com
Exercise for Healthy Aging in HIV 14-2207
Determine the best “dose” of exercise in people aging with HIV, and whether or not the dose differs from people without HIV.
Men and women aged 50-70, on antiretroviral therapy for a minimum of 2 years with no detectable viral load, CD4 count >200; no active hepatitis C or hepatitis B; no major health problems that would interfere with the ability to exercise; if diabetic, must be well-controlled on oral medications (no insulin); body mass index between 20 and 40; no current/chronic infections besides HIV.
PI: Erlandson, MD, Kristine
  • 303-724-4941
  • kristine.erlandson@ucdenver.edu
Would you like to follow your baby's brain development? Study of Pre and Postnatal Infant Brain Growth and Development 15-0707
will examine brain development during and after pregnancy, investigating different aspects of mother and infant nutritional health on your infant’s brain growth and cognitive development.  
As an expectant mother you can participate if you are less than 22 weeks pregnant; or if your healthy newborn infant is between 3 and 15 months of age.
PI: Deoni, Sean
  • 720-777-8036
  • info@childimaginglab.org
We are looking for women who have not been diagnosed with cancer to participate in a research study. 11-0357
A comparison of immune function from unaffected individuals for the study of tumor-induced immune suppression
To participate you must: - Older than 18 - Be willing to make a one-time blood donation - Not be diagnosed with an immune disease such as diabetes or rheumatoid arthritis You could make a difference in the future of women!
PI: Borges, Virginia
  • 303-724-6077
  • emily.rozzo@ucdenver.edu
Adults (18-55) and Children (8-14) with Asthma 15-1262
This research study is being done to find the amount of cockroach extract that we need to put in the nose to cause nasal symptoms.  
-Be 18 to 55 or 8 to 14 years old -Have a history of asthma
PI: Liu, Andrew
  • (720)777-8077
  • pascuala.pinedo-estrada@childrenscolorado.org
Role of Bacterial Toxins in Atopic Dermatitis HS-1962
To investigate inflammation in the skin of subjects with psoriasis and how this is different from subjects with Atopic Dermatitis
12 years or older and have a history of psoriasis
PI: Leung, Donald
  • 303-398-1409
  • bronchickc@njhealth.org
  
  
Protocol Title
14-0554Abosch, Aviva M.D.
Reclaim Deep Brain Stimulation Therapy for Obsessive-Compulsive Disorder
08-0450Abzug, Mark
IMPAACT P1063, PHASE I/II SAFETY AND EFFICACY INVESTIGATION OF ATORVASTATIN FOR TREATMENT OF INCREASED LDL CHOLESTEROL IN HIV-INFECTED CHILDREN, ADOLESCENTS, AND YOUNG ADULTS, VERSION 2.0
15-1798Accurso, Frank
Lumacaftor/Ivacaftor Combination Therapy Expanded Access Program for Patients 12 Years of Age and Older With Cystic Fibrosis Who Are Homozygous for
15-2421Accurso, Frank J MD
Compassionate use of Kalydeco-L-M
03-993Ahnen, Dennis
COLORECTAL CHEMOPREVENTION WITH CALCIUM AND VITAMIN D (THE VITAMIN D/CALCIUM POLYP PREVENTION STUDY)
11-1513Akuthota, Venu
Lumbar Epidural Steroid Injections for Spinal Stensis (LESS): Randomized Controlled Trial
13-2720Alkousakis, Theodore
A Trial to Determine the Effect of Psoriasis Treatment on Cardiometabolic Disease
13-2727Alkousakis, Theodore
Vascular Inflammation in Psoriasis Extension (VIP-E) Trial
14-1692Alkousakis, Theodore
A Phase 3, Multicenter, Randomized, Double-blind, Placebo and Active Comparator-controlled Study Evaluating the Efficacy and Safety of Guselkumab for the Treatment of Subjects with Moderate to Severe Plaque-type Psoriasis with Randomized Withdrawal and Retreatment SHORT TITLE: Janssen Voyage 2
16-0136Alkousakis, Theodore James M.D.
Determinants of delayed diagnosis in melanoma patients
15-2164Allison, Mandy A M.D.
Bright By Three (BB3) Effectiveness Trial
16-0836Alvarez, Enrique III
A multicenter, global, retrospective, observational study to characterize real-world clinical outcomes in patients with relapsing-remitting multiple sclerosis treated with disease-modifying therapies (Tecfidera®, Copaxone®, Aubagio®, or Gilenya®) (EFFECT)
02-805Anderson, Clark
RANDOMIZED EVALUATION OF RECURRENT STROKE COMPARING PFO CLOSURE TO ESTABLISHED CURRENT STANDARD OF CARE TREATMENT - RESPECT TRIAL
14-1522Armstrong, Ehrin
LIBERTY 360: Prospective, Observational, Multi-Center Clinical Study to Evaluate Acute & Long Term Clinical & Economic Outfomes of Endovascular Device Intervention in Patients with Distal Outflow Peripheral Arterial Disease (PAD)
16-0035Armstrong, Ehrin
CER-001 ATHEROSCLEROSIS REGRESSION ACS TRIAL (CARAT)
16-0058Armstrong, Ehrin
The influence of race on Percutaneous Coronary Intervention in the Veterans Affairs Healthcare System: Insights from the Veterans Affairs (VA) Clinical Assessment Reporting and Tracking (CART) Program
16-0237Armstrong, Ehrin
An international, multicenter, randomized, double-blind, placebo controlled phase 3 trial investigating the efficacy and safety of rivaroxaban to reduce the risk of major thrombotic vascular events in patients with symptomatic peripheral artery disease undergoing lower extremity revascularization procedures ("VOYAGER")
14-1169Armstrong, Ehrin
Randomized, Multicenter, Controlled Trial to Compare Best Endovascular versus Best Surgical Therapy in Patients with Critical Limb Ischemia (BEST-CLI)
14-1436Armstrong, Ehrin
Delivery of Dexamethasone to the Adventitia to eNhance Clinical Efficacy after Femoropopliteal Revascularization
14-1935Armstrong, Ehrin
Antiplatelet Strategy for Peripheral Arterial Interventions for Revascularization of Lower Extremities-ASPiRE
16-0035Armstrong, Ehrin
CER-001 ATHEROSCLEROSIS REGRESSION ACS TRIAL (CARAT)
16-0237Armstrong, Ehrin
An international, multicenter, randomized, double-blind, placebo controlled phase 3 trial investigating the efficacy and safety of rivaroxaban to reduce the risk of major thrombotic vascular events in patients with symptomatic peripheral artery disease undergoing lower extremity revascularization procedures ("VOYAGER")
16-0047Auerbach, Scott
Worldwide Experience with Pediatric Heartware® Implants
14-2135Auerbach, Scott
Therapeutic Potential for Aldosterone Inhibition in Duchenne Muscular Dystrophy
09-0945Badesch, David
A Randomized, Double-Blind, Placebo-Controlled, Phase II Multi-center trial of Monoclonal Antibody To Cd20 (Rutiximab) For The Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (Ssc-Pah)
12-0089Badesch, David
A Phase 2, Placebo Controlled, Double-Blind, Randomized, Clinical Study to Determine Safety, Tolerability and Efficacy of Pulsed, Inhaled Nitric Oxide (iNO) Versus Placebo as Add on Therapy in Symptomatic Subjects with Pulmonary Arterial Hypertension (PAH)
12-1107Badesch, David
TDE-PH-311-An Open-Label Extension Study of UT-15C in Subjects with Pulmonary Arterial Hypertension-A Long-Term Follow-Up to Protocol TDE-PH-310
13-1835Badesch, David
A multicenter, double-blind, randomized, placebo-controlled, Phase 3 study to assess the efficacy and safety of oral BPS-314d-MR added-on to treprostinil, inhaled (Tyvaso®) in subjects with pulmonary arterial hypertension.
14-0049Badesch, David
402-C-1302: A Dose-ranging Study of the Efficacy and Safety of Bardoxolone Methyl in Patients with Pulmonary Arterial Hypertension
14-0942Badesch, David
MOTION (Bayer Protocol 17407): A Phase IV, Prospective, Single-Arm, Open Label Study to Measure Outcomes in Patients with Pulmonary Arterial Hypertension not on Active Treatment.
14-0943Badesch, David
Protocol GS-357-1394: A Phase 2, Dose-ranging, Randomized, Double-blind, Placebo-controlled Study of GS-4997 in Subjects with Pulmonary Arterial Hypertension
14-1624Badesch, David
APD811-003: A Randomized, Double-blind, Parallel-group, Placebo-controlled Phase 2 Trial of APD811, an Oral IP Receptor Agonist, in Patients with Pulmonary Arterial Hypertension
14-1625Badesch, David
APD811-007: An Open-Label Extension Study of APD811-003 in Patients with Pulmonary Arterial Hypertension
16-0018Badesch, David
LIBERTY (EIG-UBX-001): A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Ubenimex in Patients with Pulmonary Arterial Hypertension.
16-0018Badesch, David B M.D.
LIBERTY (EIG-UBX-001): A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Ubenimex in Patients with Pulmonary Arterial Hypertension.
07-0535Barbour, Linda
REGULATION OF MATERNAL FUEL SUPPLY AND NEONATAL ADIPOSITY
16-0350Barnes, Sean M
ACT for Life: a Brief Intervention for Maximizing Recovery After Suicidal Crises
14-0071Barqawi, Albaha
The Immuno-Response to Primary Cryotherapy for the Treatment of Prostate Cancer
14-0663Barron, Michelle
“A multi-center, randomized, double-blind study to compare the efficacy and safety of cadazolid versus vancomycin in subjects with Clostridium difficile-associated diarrhea (CDAD).”
14-2099Barron, Michelle
A Prospective, Multicenter, Open-Label, Randomized, Comparative Study to Estimate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Oral SCY-078 vs. Standard-of-Care Following Initial Intravenous Micafungin Therapy in Treatment of Invasive Candidiasis (Including Candidemia) in Hospitalized Nonneutropenic Adults
15-1767Barron, Michelle
IRC 005: A Randomized Double-Blind, Phase 3 Study Comparing the Efficacy and Safety of High-Titer versus Low-Titer Anti-Influenza Immune Plasma for the Treatment of Severe Influenza
14-1938Bartels, Karsten
Self-reported usage patterns of opioid analgesic medications after surgery
16-0466Bastow, Brittney Dianne Thall
Should endometrial biopsy be used for diagnosing polyps?
16-0583Beard, Lauren Alexis
Central venous catheter use in the neonatal intensive care unit
12-1011Behbakht, Kian
GOG 9927- A PHASE I TRIAL OF PEGYLATED LIPOSOMAL DOXORUBICN (PLD), CARBOPLATIN AND NCI SUPPLIED VELIPARIB (ABT-888) IN RECURRENT PLATINUM SENSTIVE OVARIAN, PRIMARY PERITONEAL AND FALLOPIAN TUBE CANCER.
13-2626Behbakht, Kian
A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Patients with BRCA Mutated Advanced (FIGO Stage III-IV) Ovarian Cancer following First Line Platinum Based Chemotherapy.
13-0388Bennett, Jeffrey
A Phase IV Trial of Neuroprotection with ACTH in Acute Optic Neuritis
15-1194Bennett, Jeffrey Lawrence
A PHASE 2/3, RANDOMIZED, DOUBLE-MASKED, SHAMCONTROLLED TRIAL OF QPI-1007 DELIVERED BY SINGLE OR MULTI-DOSE INTRAVITREAL INJECTION(S) TO SUBJECTS WITH ACUTE NONARTERITIC ANTERIOR ISCHEMIC OPTIC NEUROPATHY (NAION) Sponsor Protocol No. QRK207 WIRB Protocol No. : 20141573
07-0124Beresford, Thomas
A DOUBLE-BLIND, CONTROLLED STUDY OF ARIPIPRAZOLE IN CO-MORBID SCHIZOPHRENIA AND COCAINE DEPENDENCE
08-0582Beresford, Thomas
A Double-Blind Trial of Divalproex Sodium for Affective Lability and Alcohol use Following Traumatic Brain Injury
16-0017Berman, Brian Daniel MD, MS
Diagnostic and Rating Tools for Blepharospasm
15-1772Boles, Richard E
Family and Home Environment Factors Impacting Sleep Duration During Early Childhood
08-1117Booth, Robert E
NEW TRENDS IN HIV-RELATED RISKY PATTERNS OF INJECTING DRUG USE AND DRUGS DISTRIBUTION IN FOUR EURASIAN COUNTRIES WITH SUBSTANTIAL PRESENCE OF ATDS
13-1617Borges, Virginia
A Randomized Phase II Trial of Neoadjuvant Cisplatin vs Doxorubicin/Cyclophosphamide (AC) in Women with Newly Diagnosed Breast Cancer and Germline BRCA Mutations. The INFORM: BRCA 1/2 Study: Investigation of Neoadjuvant Chemotherapy for Mutation Carriers: BRCA 1/2
15-1245Borges, Virginia
Single Patient Access (compassionate use) treatment of ONT-10, a liposomal MUC1 cancer vaccine, for patient # 0005-086
08-1222Borges, Virginia F. M.D.
Helping Ourselves, Helping Others: The Young Womens' Breast Cancer Study
15-1085Borges, Virginia F. M.D.
A PHASE 1b DOSE ESCALATION STUDY OF ADXS31-164 IN SUBJECTS WITH HER2 EXPRESSING SOLID TUMORS
15-1856Borges, Virginia F. M.D.
Phase 2 Randomized, Double-Blinded, Controlled Study of ONT-380 vs. Placebo in Combination with Capecitabine and Trastuzumab in Patients with Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma. Sponsor Protocol No. ONT-380-206. WIRB Protocol No. 20152617
16-0679Borges, Virginia F. M.D.
A Phase 3 Open-Label, Randomized, Parallel 2-Arm Multi-Center Study of Talazoparib (BMN 673) versus Physician’s Choice in Metastatic Breast Cancer, Who Have Received Prior Chemotherapy for Metastatic Disease. Sponsor protocol number 673-301 WIRB protocol number 20131243
16-0462Bourque, Stephanie L.
Back-transport of Premature Infants Admitted to CHCO NICU
13-2801Bowles, Daniel
A Randomized, Double-Blind, Placebo-Controlled Study of Chemotherapy Plus Cetuximab in Combination with VTX-2337 in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
14-0688Bowles, Daniel
A Randomized Phase 2, Double-blind, Placebo-controlled, Multi-center Study Comparing Pemetrexed in Combination with TH-302 vs Pemetrexed in Combination with Placebo in Second-line Chemotherapy for Advanced Non-Squamous, Non-Small Cell Lung Cancer
14-1232Bowles, Daniel
Randomized, Double-Blind, Multicenter, Phase 3 Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)
14-2282Bowles, Daniel
A PHASE 3B RANDOMIZED STUDY OF LENALIDOMIDE (CC-5013) PLUS RITUXIMAB MAINTENANCE THERAPY FOLLOWED BY LENALIDOMIDE SINGLE-AGENT MAINTENACE VERSUS RITYUXIMAB MAINTENANCE IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR, MARGINAL ZONE OR MANTLE CELL LYMPHOMA
14-2282Bowles, Daniel W
A PHASE 3B RANDOMIZED STUDY OF LENALIDOMIDE (CC-5013) PLUS RITUXIMAB MAINTENANCE THERAPY FOLLOWED BY LENALIDOMIDE SINGLE-AGENT MAINTENACE VERSUS RITYUXIMAB MAINTENANCE IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR, MARGINAL ZONE OR MANTLE CELL LYMPHOMA
16-0007Bradley, Steven M
Invasive Coronary Procedure Use and Outcomes among Cocaine Users - An Analysis from the Veterans Affairs CART Program
13-0092Braund, Cortney
A Randomized Controlled Trial of Nebulized 3% Hypertonic Saline vs. Standard of Care In Patients With Bronchiolitis
16-0063Bravman, Jonathan T
A retrospective analysis of two techniques for biceps tenodesis
16-0132Bravman, Jonathan T
Qualitative Outcomes and Operative Experience in Patients with Total Shoulder Arthroplasty: Comparison to Total Hip and Knee Arthroplasty
16-0643Breed, Chris
Detection of malignancy using currently available cell free fetal DNA tests
10-0875Brenner, Lisa
A pilot phase II study of hyperbaric oxygen for persistent post-concussive symptoms after mild traumatic brain injury (HOPPS)
12-0636Brenner, Lisa
Brain Injury and Mechanisms of Action of HBO2 for Persistent Post-Concussive Symptoms after Mild Traumatic Brain Injury (BIMA)
16-0802Brosnahan, Godela M. M.D.
Feasibility Study of Metformin Therapy in ADPKD
15-2242Bucknell, Allan Lee M.D.
A Characterization of the Effect of Total Knee Arthroplasty on Glycemic Control in the VA Population
12-0560Bull, Todd
TAPIT-1: Treatment of Pulmonary Hypertension Associated COPD with Inhaled Treprostinil-1
14-0789Bull, Todd
RISE IIP: A randomized, double-blind, placebo-controlled phase II study to investigate the efficacy and safety of riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in patients with symptomatic pulmonary hypertension associated with idiopathic interstitial pneumonias (IIP).
15-1254Bull, Todd
The Einstein Choice Study: Reduced-dosed rivaroxaban and standard-dosed rivaroxaban versus ASA in the long term prevention of recurrent symptomatic venous thromboembolism in patients with symptomatic deep-vein thrombosis and/or pulmonary embolism
15-2361Bull, Todd
RIN-PH-202: An Open-Label Extension study of Inhaled Treprostinil in Subjects with Pulmonary Hypertension due to Parenchymal Lung Disease
16-0394Bull, Todd Matthew M.D.
MERPHY: Measuring Resilience in the Pulmonary Hypertension Patient
16-0957Cabrera-Muffly, Cristina
Otolaryngology Resident Attrition and Applicant Matching
06-0155Camidge, David
PHASE I SAFETY, PHARMACOKINETIC AND PHARMACODYNAMIC STUDY OF PF-02341066, A C-MET/HGFR SELECTIVE TYROSINE KINASE INHIBITOR, ADMINISTERED ORALLY TO PATIENTS WITH ADVANCED CANCER.
13-2002Camidge, David
A phase II study of ponatinib in cohorts of patients with lung cancer preselected using different candidate predictive biomarkers.
13-2002Camidge, David Ross MD, PhD
A phase II study of ponatinib in cohorts of patients with lung cancer preselected using different candidate predictive biomarkers.
16-0085Camidge, David Ross MD, PhD
An open-label, multi-center, Phase IV, roll-over study in patients with ALK positive malignancies who have completed a prior Novartis-sponsored ceritinib (LDK378) study and are judged by the investigator to benefit from continued treatment with ceritinib Protocol No. CLDK378A2X01B WIRB No. 20160715
14-0514Campbell, Jeffrey
Double-blind, Placebo-controlled Randomized Controlled Trial of NSAID Prior to Ureteral Stent Removal in a Pediatric Population
16-0309Campbell, Jonathan David PhD
US Direct and Indirect Costs of Dravet Syndrome
11-0995Campbell, Thomas
ACTG A5279: Phase III Clinical Trials of Ultra-Short-Course Rifapentine/Isoniazid for the Prevention of Active Tuberculosis in HIV-Infected Individuals with Latent Tuberculosis Infection
13-2223Campbell, Thomas
A5315: A Phase I/II Study of Single Dose Romidepsin in HIV-Infected Adults with Suppressed Viremia on Antiretroviral Therapy to Assess Safety, Tolerability, and Activation of HIV-1 Expression
13-2303Campbell, Thomas
A5314: Effect of Reducing Inflammation with Low Dose Methotrexate on Inflammatory Markers and Endothelial Function in Treated and Suppressed HIV Infection
14-1057Campbell, Thomas
A5329: Interferon-Free Therapy for Chronic Hepatitis C Virus Genotype 1 Infection in Subjects with HIV-1 Coinfection Receiving Concurrent Antiretroviral Therapy
14-2056Campbell, Thomas
HIV-V-A004: A Phase 1/2a Study to Evaluate the Safety/Tolerability and Immunogenicity of Homologous Ad26 Mosaic Vector Vaccine Regimens or Ad26 Mosaic and MVA Mosaic Heterologous Vector Vaccine Regimens, with High-Dose, Low-Dose or no Clade C gp140 Protein Plus Adjuvant for HIV Prevention
14-2370Campbell, Thomas
A5324: A Randomized, Double-Blinded, Placebo-Controlled Trial Comparing Antiretroviral Intensification with Maraviroc and Dolutegravir with No Intensification or Intensification with Dolutegravir Alone for the Treatment of Cognitive Impairment in HIV
15-0023Campbell, Thomas
A5332: Randomized Trial to Prevent Vascular Events in HIV-REPRIEVE
15-0306Campbell, Thomas
A5336: A Randomized, Pilot Study of Ruxolitinib in Antiretroviral-Treated HIV-Infected Adults
15-1307Campbell, Thomas
A5346: A Randomized, Double-Blinded, Placebo-Controlled Trial of a Dipeptidyl Peptidase-4 Inhibitor (Sitagliptin, Januvia) for Reducing Inflammation and Immune Activation in HIV-Infected Men and Women
16-0083Campbell, Thomas
A5350: Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
15-0692Campbell, Thomas B M.D.
MK-1439A-024, A Phase III Multicenter, Open-Label, Randomized Study to Evaluate a Switch to MK-1439A in HIV-1-Infected Subjects Virologically Suppress Sponsor Protocol No. MK1439A-024 WIRB Protocol No. 20151193
15-1998Campbell, Thomas B M.D.
A Phase 3, Randomized, Open Label Study to Evaluate the Safety and Efficacy of Switching from Regimens Consisting of Boosted Atazanavir or Darunavir plus either Emtricitabine/ Tenofovir or Abacavir/ Lamivudine to GS-9883/ Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults. Sponsor No. GS-US-380-1878. WIRB No. 20152512
04-0831Carroll, John
A STUDY OF THE EVALVE CARDIOVASCULAR VALVE REPAIR SYSTEM (CVRS) ENDOVASCULAR VALVE EDGE-TO-EDGE REPAIR STUDY
15-2222Chan, Kenny H
AN 8-WEEK, PROSPECTIVE, MULTICENTER, OPEN-LABEL STUDY OF OTO-201 GIVEN AS A SINGLE ADMINISTRATION IN PEDIATRIC SUBJECTS WITH A HISTORY OF OTITIS MEDIA REQUIRING TYMPANOSTOMY TUBE PLACEMENT Sponsor Protocol No. 201-201507 WIRB Protocol No. 20152053
13-3022Chan, Laurence
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Efficacy and Safety of a Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seronegative Kidney Transplant Recipients Receiving an Organ from a CMV-Seropositive Donor. Sponsor Protocol No. 0113-CL-2001.
13-2360Chapman, Kevin
Cognitive AED Outcomes in Pediatric Localization Related Epilepsy (COPE)
15-0550Chase, Howard
Reduction of Nocturnal Hypoglycemia and Hyperglycemia in the Home Using Predictive Algorithms, Pump Suspension, and Insulin Dosing (PHM2)
16-0430Chase, Howard
Reduction of Nocturnal Hypoglycemia and Hyperglycemia in the Home Using Predictive Algorithms, Pump Suspension, and Insulin Dosing in Children and Young Adolescents (PHM3)
10-1066Chonchol, Michel
SYSTOLIC BLOOD PRESSURE INTERVENTION TRIAL (SPRINT)
14-1636Chonchol, Michel
A Phase 3b, Multi-center, Randomized-withdrawal, Placebo-controlled, Double-blind, Parallel-group Trial to Compare the Efficacy and Safety of Tolvaptan (45 to 120 mg/day, Split-dose) in Subjects with Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease
14-2284Chonchol, Michel
A Phase 3B, Multi-center, Open-label Trial to Evaluate the Long Term Safety of Immediate-release Tolvaptan (OPC 41061, 30 mg to 120 mg/day, Split dose) in Subjects with Autosomal Dominant Polycystic Kidney Disease - Protocol #156-13-211
16-1202Chonchol, Michel
A Phase 1b/2a, Safety, Pharmacokinetic and Dose-Escalation Study of KD019 in Subjects with Autosomal Dominant Polycystic Kidney Disease ((KD019-101)
16-0591Chonchol, Michel Benjamin M.D.
Recruitment Database Protocol for the Division of Renal Diseases and Hypertension at the University of Colorado Anschutz Medical Campus
16-1202Chonchol, Michel Benjamin M.D.
A Phase 1b/2a, Safety, Pharmacokinetic and Dose-Escalation Study of KD019 in Subjects with Autosomal Dominant Polycystic Kidney Disease ((KD019-101)
16-0081Christiansen, Cory L PT, PhD
Error-Augmentation Gait Training for People with Lower Limb Amputation
15-1280Clark, Brendan J. MD, MS
Outpatient Follow-up in Patients with Unhealthy Alcohol Use After Hospital Discharge
08-0721Cohen, Mindy
THE USE OF INTRAOPERATIVE INTRATHECAL MORPHINE VERSUS EPIDURAL EXTENDED RELEASE MORPHINE FOR POSTOPERATIVE PAIN CONTROL IN PEDIATRIC PATIENTS UNDERGOING POSTERIOR SPINAL FUSION
14-0431Collins, Abigail
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of UX007 in Subjects with Glucose Transporter Type 1 Deficiency Syndrome
16-0143Connolly, Teresa Charlotte
Predictors for readmission after one year following an ischemic stroke, hemorrhagic stroke, transient ischemic attack, and probable aborted stroke diagnosis
12-1388Corboy, John
A Double-Blind, Placebo Controlled Trial of Estriol Treatment in Women with Multiple Sclerosis: Effect on Cognition
15-2218Cost, Nicholas Glenn
Treatment-Induced Hypogonadism in Men with Testicular Cancer
11-1017Crawford, E
A Multicenter, Open-Label, Single-Arm, Phase 2 Study of Abiraterone Acetate plus Prednisone in Patients with Advanced Prostate Cancer without Radiographic Evidence of Metastatic Disease - Also called the IMAAGEN Study: IMpact of Abiraterone Acetate in Prostate Specific AntiGEN
12-0829Curtis, Donna
Immunogenicity and efficacy of high-dose trivalent inactivated seasonal influenza vaccine (Fluzone High Dose) in immunocompromised children and young adults.
15-1742Curtis, Donna Jean
A Phase II, Randomized, Double-blind, Placebo-controlled Study to Examine the Effects of DAS181 in Immunocompromised Subjects with Lower Respiratory Tract Parainfluenza Infection on Supplemental Oxygen Sponsor Protocol No. DAS181-2-05 WIRB Protocol No. 20140006
02-498Dabelea, Dana
DIABETES PREVENTION PROGRAM OUTCOMES STUDY (DPPOS)
96-008Dabelea, Dana
THE DIABETES PREVENTION PROGRAM
11-0712Damek, Denise
RTOG 0929 A RANDOMIZED PHASE I/II STUDY OF ABT-888 IN COMBINATION WITH TEMOZOLOMIDE IN RECURRENT (TEMOZOLOMIDE RESISTANT) GLIOBLASTOMA
15-0164Damek, Denise Marie
ABT-414 Alone or ABT-414 Plus Temozolomide versus Lomustine or Temozolomide for Recurrent Glioblastoma; a Randomized Phase II Study of the EORTC Brain Sponsor Protocol No. MI4-483 WIRB Protocol No. 20142384
15-1664Damek, Denise Marie
A Phase III randomized double-blind, controlled study of ICT-107 with maintenance temozolomide (TMZ) in newly diagnosed glioblastoma following resection and concomitant TMZ chemoradiotherapy; WIRB Protocol No. 20152376
16-0510Daugherty, Stacie Luther MD, MSPH
Using Values Affirmation to Reduce the Effects of Perceived Discrimination on Hypertension Disparities
15-0939Davidson, Jesse
Multicenter, open-label, dose escalation study to evaluate safety, tolerability and pharmacokinetics of RLX030 in addition to standard of care in pediatric patients from birth to &lt 18 years of age, hospitalized with acute heart failure.
15-0939Davidson, Jesse A M.D.
Multicenter, open-label, dose escalation study to evaluate safety, tolerability and pharmacokinetics of RLX030 in addition to standard of care in pediatric patients from birth to &lt 18 years of age, hospitalized with acute heart failure.
14-1720Davis, Shanlee
Body Composition in Infants with Klinefelter Syndrome and Effects of Testosterone Treatment
16-0248Davis, Shanlee M.
Cardiometabolic profiles of pubertal boys with Klinefelter syndrome with or without one year of exogenous testosterone treatment
14-0447Dayton, Michael
A prospective, post-market, clinical outcomes of the Secur-Fit Advanced Hip Stem by Stryker Orthopedics – Total Hip Arthroplasty
15-1868Deane, Kevin
Strategy to Prevent the Onset of Clinically-Apparent Rheumatoid Arthritis (StopRA)
16-0152Demarest, Scott Thomas
The Pathophysiology of Neurogenetic Conditions
14-0652Deterding, Robin
Electrical Impedance Imaging of Patients with Cystic Fibrosis
16-0056Devaraj, Kalpana Marie
Standardizing histological parameters of liver damage for heart transplant candidates
11-0684Diamond, Jennifer
A Phase II Study of the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Previously Treated Locally Advanced and Metastatic Triple-Negative Breast Cancer
15-1135Diamond, Jennifer
A phase IB study of the combination of MLN0128 (Dual TORC1/2 Inhibitor) and MLN8237 (Aurora A inhibitor, alisertib) in patients with advanced solid tumors with an expansion cohort in metastatic triple-negative breast cancer (TNBC)
11-0684Diamond, Jennifer R M.D.
A Phase II Study of the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Previously Treated Locally Advanced and Metastatic Triple-Negative Breast Cancer
16-0207Diamond, Jennifer R M.D.
A Phase 1 Study of Durvalumab and IPH2201 in Adult Subjects with Select Advanced Solid Tumors Sponsor Protocol No. D419NC00001 WIRB Protocol No. 20160517
16-0277Diamond, Jennifer R M.D.
A PHASE 1, OPEN-LABEL, NON-RANDOMIZED, DOSE-ESCALATING, SAFETY, TOLERABILITY, AND PHARMACOKINETIC STUDY OF TAS-119 IN COMBINATION WITH PACLITAXEL IN PATIENTS WITH ADVANCED SOLID TUMORS Sponsor protocol No. TO-TAS-119-101 WIRB protocol No. 20161143
15-2396Doebele, Robert Charles
A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers Sponsor Protocol No. CPI-444-001 WIRB Protocol No. 20152783
16-0208Doebele, Robert Charles
A Phase 1/2 Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of the Oral EGFR/HER2 Inhibitor AP32788 in Non-Small Cell Lung Cancer. Sponsor No. AP32788-15-101. WIRB No. 20160673
16-0329Dominguez, Samuel R MD, PhD
Colorado Group A Streptococcus Non-invasive Isolate Characterization
14-2097Dorris, Kathleen McCarthy O'Toole
Pilot study of a surgery and chemotherapy-only approach in the upfront therapy of children with WNT positive standard risk medulloblastoma
09-0822Douglas, Ivor
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF DEXMEDETOMIDINE (PRECEDEX®), WITH LORAZEPAM RESCUE, FOR THE MANAGEMENT OF SEVERE ALCOHOL WITHDRAWAL SYNDROME (AWS) AND ALCOHOL WITHDRAWAL DELIRIUM (AWD)
12-0570Douglas, Ivor
The MIND-USA Study Modifying the Impact of ICU-Associated Neurological Dysfunction
16-0647Douglas, Ivor S. M.D.
Prospective Observational Study of the Risk Factors for Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (HABP/VABP)
16-0432Drees, Cornelia Natascha M.D.
Database for Research on Efficacy, Safety, Outcome and Improvement of Epilepsy Surgery
16-0645Driscoll, Kimberly A
Intervention to Reduce Fear of Hypoglycemia and Optimize Type 1 Diabetes Outcomes
15-0464Dunnick, Cory
A phase II, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of lebrikizumab in patients with persistent moderate to severe atopic dermatitis that is inadequately controlled by topical corticosteroids. Short Title: Roche AD
03-1250Eckhardt, Sue
A CONTINUATION PROTOCOL FOR PI-88 IN PATIENTS WITH ADVANCED MALIGNANCIES
00-954Elias, Anthony
SWOG N9831 PHASE III TRIAL OF DOXORUBICIN AND CYCLOPHOSPHAMIDE (AC) FOLLOWED BY WEEKLY PACLITAXEL WITH OR WITHOUT TRASTUZUMAB AS ADJUVANT TREATMENT FOR WOMEN WITH HER-2 OVEREXPRESSING NODE POSITIVE OR HIGH-RISK NODE NEGATIVE BREAST CANCER
05-1078Elias, Anthony
SWOG 0307 PHASE III TRIAL OF BISPHOSPHONATES AS ADJUVANT THERAPY FOR PRIMARY BREAST CANCER
07-0325Elias, Anthony
S0622 PHASE II STUDIES OF TWO DIFFERENT SCHEDULES OF DASATINIB (NSC-732517) IN BONE-METASTASIS PREDOMINANT METASTATIC BREAST CANCER.
08-0192Elias, Anthony
ALTTO: ADJUVANT LAPATINIB AND/OR TRASTUZUMAB TREATMENT OPTIMIZATION STUDY. A RANDOMIZED MULTICENTER OPEN LABEL PHASE III STUDY OF ADJUVANT LAPATINIB TRASTUZUMAB THEIR SEQUENCE AND THEIR COMBINATION IN PATIENTS WITH HER2/ERBB2 POSITIVE PRIMARY BREAST CANCER
10-0374Elias, Anthony
I-SPY 2 TRIAL: (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging and MoLecular Analysis 2)
10-0379Elias, Anthony
PARP Inhibition after Preoperative Chemotherapy in Patients with Triple Negative Breast Cancer or ER/PR +, HER2 negative with known BRCA1/2 Mutations
11-0795Elias, Anthony
S0800 A Randomized Phase II Trial of Weekly Nanoparticle Albumin Bound Paclitaxel (NAB-Paclitaxel) (NSC-736631) with or without Bevacizumab, Either Preceded by or Followed by Q 2 Week Doxorubicin (A) and Cyclophosphamide (C) plus Pegfilgrastim (Peg-G) as Neoadjuvant Therapy for Inflammatory and Locally Advanced Her-2/NEU Negative Breast Cancer
15-0744Elias, Anthony
RTOG-1201: A Phase II Randomized Trial Evaluating the Addition of High or Standard Intensity Radiation to Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Cancer
15-2006Elias, Anthony
A Randomized, Open-Label, Phase 2 Trial of CMB305 (Sequentially Administered LV305 and G305) and Atezolizumab in Patients with Locally Advanced, Relap
15-2006Elias, Anthony David M.D.
A Randomized, Open-Label, Phase 2 Trial of CMB305 (Sequentially Administered LV305 and G305) and Atezolizumab in Patients with Locally Advanced, Relap
01-410Elias, Ellen
CHOLESTEROL AND ANTIOXIDANT TREATMENT IN PATIENTS WITH THE SMITH-LEMLI-OPITZ SYNDROME (SLOS)
13-0049Erickson, Mark
Minimize Implants Maximize Outcome Clinical Trial
10-0894Everson, Greg
NON-INVASIVE ASSESSMENT OF DISEASE PROGRESSION IN PRIMARY SCLEROSING CHOLANGITIS
13-2797Fadell, Michael
Intra articular injections with platelet rich plasma in patients with Juvenile OCD of the knee: Does it Help? A clinical and MR study.
15-2042Feldman, Amy G.
Immune Response and Clearance of Viral DNA Following Administration of Live Attenuated Varicella Vaccine in Children with Liver Disease
16-0672Fillon, Sophie Anne Laure PhD
Effect of acid blockade on microbiota and inflammation in CF.
15-1865Fischer, Aryeh M.D.
A double blind, randomised, placebo-controlled trial evaluating efficacy and safety of oral nintedanib treatment for at least 52 weeks in patients with ‘Systemic Sclerosis associated Interstitial Lung Disease’ (SSc-ILD) Sponsor Protocol No. 1199.214 WIRB Protocol No. 20152411
16-0829Fischer, Stacy Marie M.D.
Caregiver-guided pain management training in palliative care
08-0866Flaig, Thomas
CHAARTED: CHEMOHORMONAL THERAPY VS ANDROGEN ABLATION RANDOMIZED TRIAL FOR EXTENSIVE DISEASE IN PROSTATE CANCER
12-0762Flaig, Thomas
BNIT-PRV-301 A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic, Castrate-Resistant Prostate Cancer
15-2371Flaig, Thomas William M.D.
A Multinational, Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Sponsor Protocol 9785-CL-0335 WIRB Protocol No. 20160805
15-0140Fleischer, David Mark M.D.
A DOUBLE-BLIND, PLACEBO-CONTROLLED RANDOMIZED TRIAL TO STUDY THE VIASKIN MILK EFFICACY AND SAFETY FOR TREATING IgE-MEDIATED COW’S MILK ALLERGY IN CHILDREN (MILES STUDY) Sponsor Protocol No. MILES WIRB Protocol No. 20141789
15-1559Fleischer, David Mark M.D.
A Double blind, Placebo controlled, Randomized Phase III Pivotal Trial to Assess the Efficacy and Safety of Peanut Epicutaneous Immunotherapy with Viaskin® Peanut in Peanut allergic Children (PEPITES Study) Sponsor Protocol No. PEPITES WIRB Protocol No. 20152047
16-0671Fluke, John Davidson
Retrospective Collection of Child Protective Service Reports among National Early Head Start Research and Evaluation Project Participants
04-0625Foreman, Nicholas
ACNS0331: A STUDY EVALUATING LIMITED TARGET VOLUME BOOST IRRADIATION AND REDUCED DOSE CRANIOSPINAL RADIOTHERAPY (18.00 GY) AND CHEMOTHERAPY IN CHILDREN WITH NEWLY DIAGNOSED STANDARD RISK MEDULLOBLASTOMA: A PHASE III DOUBLE RANDOMIZED TRIAL
15-2353Forman, Lisa M M.D.
A PHASE 2, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, MULTIPLE CENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFICACY OF NGM282 ADMINISTERED FOR 12 WEEKS IN PATIENTS WITH PRIMARY SCLEROSING CHOLANGITIS (PSC). Sponsor No. 15-0106. WIRB No. 20152633
08-0384Frank, Guido
VIRTUAL REALITY: A NEW TOOL TO TREAT EATING DISORDERS
11-0459Freedman, Robert
NICOTINIC RECEPTORS AND SCHIZOPHRENIA: PHASE 2
14-1348Fullerton, David
Medtronic PERIcardial SurGical AOrtic Valve ReplacemeNt Pivotal Trial (PERIGON)
07-0223Furuta, Glenn
EOSINOPHILS AND INTESTINAL INFLAMMATION
16-0540Gandhi, Roopa P
An Evaluation Of Parental Preferences Regarding Dental Services For Children With Special Health Care Needs
01-284Gardner, Edward
A STUDY OF THE EFFECTIVENESS AND TOLERABILITY OF WEEKLY RIFAPENTINE/ISONIAZID FOR THREE MONTHS VERSUS DAILY ISONIAZID FOR NINE MONTHS FOR THE TREATMENT OF LATENT TUBERCULOSIS INFECTION [TBTC STUDY 26]
08-0175Gardner, Edward
CLOFAZIMINE USE IN LONG-TERM TREATMENT OF LEPROSY (PHASE III)
09-0124Gardner, Edward
STRATEGIC TIMING OF ANTIRETROVIRAL TREATMENT (START 001), VERSION 2.0, 25 OCTOBER 2010
12-0003Gardner, Edward
Compassionate Use of Ibalizumab for the Treatment of HIV Infection
14-0658Gardner, Edward
Benznidazole for treatment of Chagas Disease
14-1706Gardner, Edward
Anti-Influenza Hyperimmune Intravenous Immunoglobulin Clinical Outcome Study (INSIGHT 006: FLU-IVIG)
15-1186Gardner, Edward
Randomized Trial to Prevent Vascular Events in HIV – REPRIEVE (A5332)
15-1466Gardner, Edward
ANCHOR Study: Anal Cancer/HSIL Outcomes Research Study (AMC Protocol #A01)
16-0724Garg, Kavita
Perceptions, Barriers and Expectations by a Diverse Patient Population Undergoing Routine Computerized Tomography (CT) Imaging
14-2330Garg, Satish K
Protocol for the Evaluation of Dario™ BGMS Performance at Elevated Altitude. Sponsor Protocol No. CP-0003; WIRB Protocol No. 20142637
15-0036Garg, Sumeet
Use of Ultrasonic Bone Scalpel in Adolescent Idiopathic Scoliosis - Randomized Clinical Trial
16-0522Garg, Sumeet
Failure and Complication rates in Spinal Fusion for the Treatment of Pediatric Spondylolisthesis
16-0762Garg, Sumeet
Adverse reactions and Vancomycin powder use in the EOS population
13-2281Garg, Sumeet
Validation of triggered EMG values for pedicles screws using a powered screwdriver
03-683Garrington, Timothy
AHOD0031, A PHASE III GROUP-WIDE STUDY OF DOSE-INTENSIVE RESPONSE-BASED CHEMOTHERAPY AND RADIATION THERAPY FOR CHILDREN AND ADOLESCENTS WITH NEWLY DIAGNOSED INTERMEDIATE RISK HODGKIN DISEASE
15-0442Garrington, Timothy
A Phase 2/3, Open-label, Single Arm, Multicenter Study to Assess Safety, Tolerability, Pharmacokinetics and Efficacy of Intravenous Multiple Administrations of NI -0501, an Anti-interferon Gamma (Anti-IFNγ) Monoclonal Antibody, in Pediatric Patients with Primary Hemophagocytic Lymphohistiocytosis(HLH)
16-0368Garrington, Timothy
A Multicenter Study for the Long-term Follow-up of HLH Patients who Received Treatment with NI-0501, an Anti-interferon Gamma Monoclonal Antibody (NI-0501-05-US-P-IND#111015)
15-2032Gaspar, Laurie Elizabeth M.D.
Physician Survey: Prophylactic Cranial Irradiation for Limited Small Cell Lung Cancer
16-0725Georgopoulos, Gaia
Incidence of Hip Dysplasia in Patients with Prader Willi Syndrome
12-1408Gerich, Mark
Randomized, double blind, prospective trial investigating the efficacy of Methotrexate in induction and maintenance of steroid free remission in ulcerative colitis (Methotrexate Response In Treatment of UC - Merit-UC).
03-239Giller, Roger
AALL0031 A CHILDREN'S ONCOLOGY GROUP PILOT STUDY FOR THE TREATMENT OF VERY HIGH RISK ACUTE LYMPHOBLASTIC LEUKEMIA IN CHILDREN AND ADOLESCENTS
10-1009Giller, Roger
Defibrotide for Patients with Hepatic Veno-Occlusive Disease (VOD): A Treatment IND Study
13-0299Giller, Roger
Allogeneic hematopoietic cell transplantation for patients with nonmalignant inherited disorders using a Treosulfan based preparative regimen (FHCRC 2256.00)
14-1059Giller, Roger
A Phase 3, Open-label, Multicenter Study of the Safety/Tolerability and Efficacy of Brincidofovir (CMX001) for the prevention of Adenovirus (AdV) Disease in Subjects with Asymptomatic AdV Infection at Risk of Progression and for the Treatment of Subjects with Localized or Disseminated AdV Disease
15-0676Giller, Roger
Abatacept Combined with a Calcineurin Inhibitor and Methotrexate for Graft Versus Host Disease Prophylaxis
16-0225Giller, Roger
An Intermediate-size, Expanded Access Protocol to Provide Brincidofovir for the Treatment of Serious Adenovirus Infection or Disease (CMX001-351)
15-2279Giller, Roger H
Review of Outcomes of Bone Marrow Transplant (BMT) Patients
16-0611Giller, Roger H
A Prospective Observational Study for the Long-term Follow-up of Subjects Previously Enrolled in Selected Clinical Studies of CMX001 (“The Chimerix CMX001 Registry”) PROTOCOL No. CMX001-333
09-0899Ginde, Adit
VITAMIN D SUPPLEMENTATION AND ACUTE RESPIRATORY INFECTION IN OLDER NURSING HOME RESIDENTS
15-2239Gist, Katja M.
Platelet and tissue cAMP: novel biomarkers of milrinone efficacy in children
14-1979Glass, Nina
Comparison of Epidural and Paracostal Catheter Placement for Pain Control After Rib Fractures
15-2213Gonzalez, Rene M.D.
A Phase I Safety Pilot/Phase II, Open-label Study of Varlilumab (CDX-1127) in Combination with Ipilimumab and CDX-1401 in Patients with Unresectable Stage III or IV Melanoma Sponsor Protocol No. CDX1127-03 WIRB Protocol No. 20151409
16-0302Gonzalez, Rene M.D.
Phase IIIb/IV, Randomized, Double Blinded, Study of Nivolumab 3 mg/kg in Combination with Ipilimumab 1 mg/kg vs Nivolumab 1 mg/kg in Combination with Ipilimumab 3 mg/kg in Subjects with Previously Untreated, Unresectable or Metastatic Melanoma. Sponsor No. CA209511. WIRB No. 20160718
16-0429Gonzalez, Rene M.D.
A MULTICENTER, OPEN-LABEL, PHASE 1B CLINICAL STUDY OF CMP-001 IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WHO HAVE BEEN TREATED WITH PEMBROLIZUMAB FOR ADVANCED MELANOMA, Protocol No. CMP-001-001 WIRB No. 20152597
05-0913Gore, Lia
ADVL04P2, A FEASIBILITY PILOT AND PHASE 2 STUDY OF CHEMOIMMUNOTHERAPY WITH EPRATUZUMAB (IND# 12034) FOR CHILDREN WITH RELAPSED CD22-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)
10-0479Gore, Lia
ADVL0912, A Phase ½ Study of PF-02341066, an Oral Small Molecule Inhibitor of Anaplastic Lymphoma Kinase (ALK) and C-MET, in Children with Relapsed/Refractory Solid Tumors and Anaplastic Large Cell Lymphoma
11-1455Gore, Lia
A PHASE I/II STUDY OF BRENTUXIMAB VEDOTIN (SGN-35) IN PEDIATRIC PATIENTS WITH RELAPSED OR REFRACTORY SYSTEMIC ANAPLASTIC LARGE-CELL LYMPHOMA OR HODGKIN LYMPHOMA
12-1294Gore, Lia
A Phase II Trial of Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients with Relapsed/Refractory Ewing's Sarcoma and Neuroblastoma
12-1361Gore, Lia
A Pilot Study of Decitabine and Vorinostat with Chemotherapy for Relapsed ALL (PRMC 12-123)
13-0055Gore, Lia
A Phase 2 Study of Ipilimumab in Children and Adolescents (12 to &lt18 years) with Previously Treated or Untreated, Unresectable Stage III or Stage IV Malignant Melanoma
13-0078Gore, Lia
A feasibility trial of everolimus (RAD001), an mTOR inhibitor, given in combination with multiagent re-induction chemotherapy in pediatric patients with relapsed acute lymphoblastic leukemia (ALL)
14-0832Gore, Lia
A Phase I Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients with Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene
14-1388Gore, Lia
Phase I trial of selective inhibitor of nuclear export, KPT-330, in relapsed childhood ALL and AML (DFCI #13-563)
15-1824Gore, Lia
A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Pediatric and Adolescent Subjects with Relapsed/Refractory B-precursor
09-0667Gottlieb, Peter
THE EFFECTS OF OPEN LABEL ALPHA1-ANTITRYPSIN ON THE PROGRESSION OF TYPE 1 DIABETES IN SUBJECTS WITH DETECTABLE C-PEPTIDE
10-1074Gottlieb, Peter
Anti-CD3 MAB (eplizumab) for Prevention of Diabetes in Relatives at-Risk for Type 1 Diabetes Mellitus
11-0260Gottlieb, Peter
Inducing Remission in New Onset E1dm with Alefacept (Amevive)
12-1578Gottlieb, Peter
CTLA-4Ig (Abatacept) for Prevention of Abnormal Glucose Tolerance and Diabetes in Relatives At-Risk for Type 1 Diabetes Mellitus (Protocol TN-18)
13-2652Gottlieb, Peter
Safety and Efficacy of Imatinib for Preserving Beta-cell Function in New-onset Type 1 Diabetes Mellitus
13-2824Gottlieb, Peter
A Phase II Trial to Examine the Effect of Subcutaneous Exenatide (Bydureon) on Glucose Control in Patients with Type 1 Diabetes
14-2142Gottlieb, Peter
Antithymocyte Globulin (ATG) and Pegylated Granulocyte Colony Stimulating Factor (GCSF) in New Onset Type 1 Diabetes (Protocol TN-19)
15-1352Gottlieb, Peter Ashley M.D.
MER3101: MAS-1 ADJUVANTED ANTIGEN-SPECIFIC IMMUNOTHERAPEUTIC FOR PREVENTION AND TREATMENT OF TYPE 1 DIABETES
16-0487Grabowski, Alena Marie
Development of a Novel Device to Measure Socket Pistoning
01-932Greffe, Brian
ANBL0032 PHASE III RANDOMIZED STUDY OF CHIMERIC ANTIBODY 14.18 (CH 14.18) IN HIGH RISK NEUROBLASTOMA FOLLOWING MYELOABLATIVE THERAPY AND AUTOLOGOUS STEM CELL RESCUE
04-0119Greffe, Brian
AEWS0331, EUROPEAN EWING TUMOR WORKING INITIATIVE OF NATIONAL GROUPS, EWING TUMOR STUDIES 1999 (EURO-E.W.I.N.G. 99)
01-101Guntupalli, Saketh
GOG#184 - A RANDOMIZED PHASE III STUDY OF TUMOR VOLUME DIRECTED PELVIC PLUS OR MINUS PARA-AORTIC IRRADIATION FOLLOWED BY CISPLATIN AND DOXORUBICIN OR CISPLATIN, DOXORUBICIN AND PACLITAXEL FOR ADVANCED ENDOMETRIAL CARCINOMA
07-1235Guntupalli, Saketh
GOG 0213 PHASE III RANDOMIZED CONTROLLED CLINICAL TRIAL OF CARBOPLATIN AND PACLITAXEL (OR GEMCITABINE) ALONE OR IN COMBINATION WITH BEVACIZUMAB (NSC #704865, IND # 113912) FOLLOWED BY BEVACIZUMAB AND SECONDARY CYTOREDUCTIVE SURGERY IN PLATINUM SENSITIVE RECURRENT OVARIAN, PERITONEAL PRIMARY AND FALLOPIAN TUBE CANCER. NCI-SUPPLIED AGENTS: BEVACIZUMAB (NSC #704865, IND #113912)
11-0110Guntupalli, Saketh
GOG 0170Q - A Phase II Evaluation of Intraperitoneal EGEN-001 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer)(IND #14350) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
11-0636Guntupalli, Saketh
GOG 9923 - A PHASE I STUDY OF INTRAVENOUS CARBOPLATIN/PACLITAXEL OR INTRAVENOUS AND INTRAPERITONEAL PACLITAXEL/CISPLATIN IN COMBINATION WITH CONTINUOUS OR INTERMITTENT / /CTEP SUPPLIED AGENT ABT-888 (NSC #737664) AND CTEP-SUPPLIED AGENT BEVACIZUMAB (NSC #704865) IN NEWLY DIAGNOSED PATIENTS WITH PREVIOUSLY UNTREATED EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER
13-2371Guntupalli, Saketh
GOG-0186K: A RANDOMIZED PHASE II STUDY OF NCI SUPPLIED CABOZANTINIB (NSC #761968 IND #116059) VERSUS WEEKLY PACLITAXEL (NSC #673089) IN THE TREATMENT OF PERSISTENT OR RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER
14-2392Guntupalli, Saketh
A Randomized Phase II Trial of Everolimus and Letrozole or Hormonal Therapy (Tamoxifen/Medroxyprogesterone Acetate) in Women with Advanced, Persistent, or Recurrent Endometrial Carcinoma
15-0187Guntupalli, Saketh
The Safety of Oral Apixaban (Eliquis) versus Subcutaneous Enoxaparin (Lovenox) for Thromboprophylaxis in Women with Suspected Pelvic Malignancy; a Prospective Randomized Open Blinded End-point (PROBE) Design
11-0636Guntupalli, Saketh Ram
GOG 9923 - A PHASE I STUDY OF INTRAVENOUS CARBOPLATIN/PACLITAXEL OR INTRAVENOUS AND INTRAPERITONEAL PACLITAXEL/CISPLATIN IN COMBINATION WITH CONTINUOUS OR INTERMITTENT / /CTEP SUPPLIED AGENT ABT-888 (NSC #737664) AND CTEP-SUPPLIED AGENT BEVACIZUMAB (NSC #704865) IN NEWLY DIAGNOSED PATIENTS WITH PREVIOUSLY UNTREATED EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER
16-0381Gutierrez, Peter M
Military Suicide Research Consortium: Extensions to New Opportunities and Challenges
09-0736Gutman, Jonathan
TRANSPLANTATION OF UMBILICAL CORD BLOOD IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES USING A REDUCED-INTENSITY PREPARATIVE REGIMEN
11-0199Gutman, Jonathan
A Randomized Phase III Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD after Unrelated Donor Hematopoietic Cell Transplantation using Nonmyeloblative Conditioning for Patients with Hematologic Malignancies: A Multi-Center Trial
11-0876Gutman, Jonathan
10-CBA: A Multi-Center Access And Distribution Protocol For Unlicensed Cryopreserved Cord Blood Units (CBUs) For Transplantation In Pediatric And Adult Patients With Hematologic Malignancies And Other Indications
12-0096Gutman, Jonathan
A multicenter safety study of unlicensed, investigational cryopreserved cord blood units (CBUs) manufactured by the National Cord Blood Program (NCBP) and provided for unrelated hematopoietic stem cell transplantation of pediatric and adult patients
12-1250Hak, David
Predicting Acute Compartment Syndrome (PACS) using Optimized clinical Assessment, Continuous Pressure Monitoring, and Continuous Tissue Oximetry
14-0258Hak, David
Prospective Randomized Trial to Assess PO versus IV Antibiotics for the Treatment of Early Post-op Wound Infection after Extremity Fractures (POvIV Study)
16-0871Hak, David J
Fracture blisters and surgical site infection: A retrospective study
15-2364Halbower, Ann C
Comparative Validation of a Non-invasive Contactless Device for the Diagnosis of Sleep Disorder Breathing
11-0824Hammerberg, Eric
FIXATION USING ALTERNATIVE IMPLANTS FOR THE TREATMENT OF HIP FRACTURES (FAITH): A MULTI-CENTER, RANDOMIZED TRIAL COMPARING SLIDING HIP SCREWS AND CANCELLOUS SCREWS ON REVISION SURGERY RATES AND QUALITY OF LIFE IN THE TREATMENT OF FEMORAL NECK FRACTURES
12-0563Handler, Michael
Phase II Trial of Molecularly Determined Treatment of Children and Young Adults with Newly Diagnosed Diffuse Intrinsic Pontine Gliomas
16-0622Hankinson, Todd MD
Incidence of cataract development in pediatric patients receiving craniospinal radiation
16-1052Hankinson, Todd MD
HCRN Core Data Project: Characterizing Patient Populations in the Hydrocephalus Clinical Research Network (HCRN) (HCRN Registry)
04-0005Hassell, Kathryn
CLINICAL CORRELATION AND COST ANALYSIS OF SICKLE CELL PATIENTS UNDERGOING CHRONIC ERYTHROCYTAPHERESES.
14-0713Hassell, Kathryn
A Phase II, Multicenter, Randomized, Placebo Controlled, Double-Blind, 12-Month Study to Assess Safety and Efficacy of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients with Sickle Cell-Related Pain Crisis
15-0391Hassell, Kathryn L M.D.
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Rivipansel (GMI-1070) in the Treatment of Vaso-Occlusive Crisis in Hospitalized Subjects with Sickle Cell Disease
12-0552Hattler, Brack
Cantos Trial: A Randomized, Double-Blind, Placebo-Controlled, Event-Driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-Myocardial Infarction Patients with Elevated hsCRP
13-0352Hattler, Brack
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of Alicrocumab on the Occurrence of Cardiovascular Events in Patients Who have Recently Experienced an Acute Coronary Syndrome
11-0042Haugen, Bryan
A Phase II Study of GW786034 (Pazopanib) in Advanced Thyroid Cancer
13-2567Haugen, Bryan
Phase 2 Study of Pioglitazone in follicular-patterned thyroid cancers that contain the PAX8-PPARgamma fusion gene
13-2640Haugen, Bryan
Evaluating sensitization to radioiodine therapy in patients completing a phase 2 study of Pioglitazone in follicular-patterned thyroid cancers that contain the PAX8-PPARgamma fusion gene
13-3050Haugen, Bryan
Phase I/II trial of Cediranib alone or Cediranib and Lenalidomide in iodine 131-refractory differentiated thyroid cancer
15-1932Haugen, Bryan
Randomized Double-Blind Phase II Study of Radioactive Iodine (RAI) in Combination with Placebo or Selumetinib for the Treatment of RAI-Avid Recurrent/Metastatic Thyroid Cancers
15-1932Haugen, Bryan R M.D.
Randomized Double-Blind Phase II Study of Radioactive Iodine (RAI) in Combination with Placebo or Selumetinib for the Treatment of RAI-Avid Recurrent/Metastatic Thyroid Cancers
16-0448Hayes-Diges, Autumn Tennille
A Caregiver Education Program: Case Study
07-1223Heard, Kennon
A PHASE III MULTI-CENTER CLINICAL TRIAL OF ANALATRO [ANTIVENIN LATRODECTUS (BLACK WIDOW) EQUINE IMMUNE F(AB)2] IN PATIENTS WITH SYSTEMIC LATRODECTISM
13-2883Heppe, Daniel
Preventing Alcohol Withdrawal Syndrome with Oral Baclofen: A Randomized, Placebo Controlled Trial
13-2738Hermesch, Amy
Postpartum Hemorrhage Prevention in Patients with Preeclampsia (PHP3 Study)
11-0628Heyborne, Kent
ANTENATAL LATE PRETERM STEROIDS (ALPS): RANDOMIZED PLACEBO-CONTROLLED TRIAL
12-0030Heyborne, Kent
Pilot Phase: A Randomized Trial of Fetal ECG ST Segment and T Wave Analysis as an Adjunct to Electronic Fetal Heart Rate Monitoring (STAN)
12-0031Heyborne, Kent
A Randomized Trial of Fetal ECG ST Segment and T Wave Analysis as an Adjunct to Electronic Fetal Heart Rate Monitoring (STAN)
12-0128Heyborne, Kent
A Randomized Trial to Prevent Congenital Cytomegalovirus (CMV)
14-0193Hildreth, Kerry
Vascular mechanisms for the effects of loss of ovarian hormone function on cognition in women
14-0193Hildreth, Kerry L. MD
Vascular mechanisms for the effects of loss of ovarian hormone function on cognition in women
14-0383Hill, James O PhD
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Assessing the Effect of Gelesis100 on Body Weight in Overweight and Obese Subjects with and without Type 2 Diabetes. Sponsor Protocol No. G-04. WIRB Protocol No. 20150046
16-0460Hoffman, Amanda L
Mind-body interventions utilized by occupational therapists in a medical intensive care unit: A pilot study of safety, feasibility, and patient’s perception of benefit
15-1389Holers, Vernon Michael MD
Accelerating Medicines Partnership: Evolving Adaptive and Effector Mechanisms in Rheumatoid Arthritis
16-0648Hoopes, Andrea Jeanne MD
Adolescent-centered IUD counseling in pediatric primary care
15-1160Hoppe, Jordana Ellway
A Phase 3, Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor in Subjects Aged 6 Years and Older with Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation. Sponsor Protocol No. VX15-809-110. WIRB Protocol No. 20151062
16-0814Huguelet, Patricia S M.D.
Does utilization of a mobile app in adolescents improve compliance with recording monthly blood loss?
15-1484Hutaff-Lee, Christa F Ph.D.
Novel Assessment of Neuropsychological Difficulties in Children (NAND-Child)
16-0563Ipaktchi, Kyros R
A Multi Center Prospective Observational Study of Nerve Repair and Reconstruction Associated with Major Extremity Trauma
14-0603Jaggers, James
HALO Clinical Study: A single arm, prospective, non-randomized, multi-center clinical investigation of the SJMTM Masters HPTM 15mm Rotatable Mechanical Heart Valve
10-0625Jalal, Diana
Is Uric Acid a Mediator of Endothelial Dysfunction in Patients with Chronic Kidney Disease?
13-2362Janas, Joanne
H6D-MC-LVJJ: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 trial of Tadalafil for Duchenne Muscular Dystrophy
13-2405Janoff, Edward
Mechanisms of Impaired HIV-associated B cell and Pneumococcal Vaccine Responses
16-1013Janosy, Norah Ruth M.D.
Are anesthesiologists feeling the burn(out)? Self Reported stress levels among attendees at the Society for Education in Anesthesia (SEA) Wellness workshop
04-0579Jenkins, Herman
MET FULLY IMPLANTABLE OSSICULAR STIMULATOR
13-0028Jenkins, Timothy
A Multi-Center, Randomized, Open-Label, Comparative Study to Assess the Safety and Efficacy of a Treatment Algorithm to Reduce the Use of Vancomycin in Adult Patients with Blood Stream Infections due to Staphylococci.
15-1573Jimeno, Antonio
Phase Ib/II trial of IPH2201 And Cetuximab in patients with HPV (+) and HPV (-) recurrent or metastatic squamous cell carcinoma of the head and neck Sponsor Protocol No. IPH2201-203 WIRB Protocol No.20151898
16-0306Jimeno, Antonio
A Phase 1/1b Trial of MK-1966-001 in Combination with SD-101 in Subjects with Advanced Malignancies Sponsor Protocol No.MK-1966-01 WIRB Protocol No. 20160895
12-1189Jimeno, Antonio
A Phase 1 Pharmacokinetic (PK), Safety, And Tolerability Study Of Paclitaxel Injection Concentrate For Nano-Dispersion (PICN) Administered Weekly In Subjects With Advanced Solid Malignancies In Us Population
15-0506Jimeno, Antonio
Single Patient IND: Expanded Access Use of rigosertib for patient # 01-10
07-0084Johnson, David
APPLICATION FOR HUMANITARIAN USE DEVICE/HDE. HDE NUMBER: 980006 THERASPHERE
15-1296Johnson, David Thor
A Phase III Clinical Trial Evaluating TheraSphere® in Patients with Metastatic Colorectal Carcinoma of the Liver who have Failed First Line Chemotherapy (EPOCH) Protocol No. TS-102 WIRB No. 20111558
16-0360Johnson, Monique Gurgel
Foley Catheter Versus Oxytocin for Labor Induction in Women with Term and Near Term Premature Rupture of Membranes: A Randomized Clinical Trial (FOLCROM TRIAL)
10-0078Johnson, Richard
STUDY OF COBALT'S ROLE IN EXCESSIVE ERYTHROCYTOSIS AMONG HIGH ALTITUDE DWELLERS IN CERRO DE PASCO, PERU
12-0763Jone, Pei-Ni
Phase I/IIa Study of Pharmacokinetics, Safety, and Activity of Atorvastatin in Children with Coronary Artery Abnormalities Secondary to Kawasaki Disease.
16-0470Jones, Teresa Shyr
Perioperative central volume status in older surgical patients
13-0328Jovanovich, Anna
Phosphate Lowering to Treat Vascular Dysfunction in Chronic Kidney Disease
15-0384Jovanovich, Anna
Phosphorus Balance Study
16-0148Kabos, Peter MD
PHASE 1B STUDY TO ASSESS THE SAFETY, TOLERABILITY, AND CLINICAL ACTIVITY OF GEDATOLISIB IN COMBINATION WITH PALBOCICLIB AND EITHER LETROZOLE OR FULVESTRANT IN WOMEN WITH METASTATIC OR LOCALLY ADVANCED/RECURRENT BREAST CANCER (MBC) Protocol No. B2151009 WIRB No. 20160661
10-0095Karam, Sana
RTOG 0920 A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer
11-1658Karam, Sana
Phase 1 Trial of Olaparib (AZD2281) in Combination with C225 and Radiation Therapy in Patients With Locally Advanced, Stage IVA-B Squamous Cell Carcinomas of the Head/Neck with Heavy Smoking Histories.
12-0414Karam, Sana
RTOG 1016 Phase III Trial of Radiotherapy Plus Cetuximab versus Chemoradiotherapy in HPV-Associated Oropharynx Cancer
07-1207Kavanagh, Brian
PHASE I & II STUDY OF STEREOTACTIC BODY RADIATION THERAPY (SBRT) FOR LOW AND INTERMEDIATE RISK PROSTATE CANCER
08-0397Kavanagh, Brian
RTOG 0538 PHASE III COMPARISON OF THORACIC RADIOTHERAPY REGIMENS IN PATIENTS WITH LIMITED SMALL CELL LUNG CANCER ALSO RECEIVING CISPLATIN OR CARBOPLATIN AND ETOPOSIDE
08-1383Kavanagh, Brian
A PHASE III TRIAL OF SHORT TERM ANDROGEN DEPRIVATION WITH PELVIC LYMPH NODE OR PROSTATE BED ONLY RADIOTHERAPY (SPPORT) IN PROSTATE CANCER PATIENTS WITH A RISING PSA AFTER RADICAL PROSTATECTOMY RTOG 0534
10-1101Kavanagh, Brian
RTOG 0815: A PHASE III PROSPECTIVE RANDOMIZED TRIAL OF DOSE-ESCALATED RADIOTHERAPY WITH OR WITHOUT SHORT-TERM ANDROGEN DEPRIVATION THERAPY FOR PATIENTS WITH INTERMEDIATE-RISK PROSTATE CANCER
12-1359Kavanagh, Brian
Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial RTOG 0924
13-0192Kavanagh, Brian
Phase III Trial of Dose Escalated Radiation Therapy and Standard Androgen Deprivation Therapy (ADT) with a GNRH Agonist vs. Dose Escalated Radiation Therapy and Enhanced ADT with a GNRH Agonist and TAK-700 for Men with High-Risk Prostate Cancer RTOG 1115
13-2423Kavanagh, Brian
LCCC 1123: Phase II Study Of Stereotactic Radiosurgery or Other Local Ablation Followed by Erlotinib for Patients with EGFR Mutation Who Have Previously Progressed on an EGFR Tyrosine Kinase Inhibitor (TKI)
13-3160Kavanagh, Brian
RTOG 1205 RANDOMIZED PHASE II TRIAL OF CONCURRENT BEVACIZUMAB AND RE-IRRADIATION VERSUS BEVACIZUMAB ALONE AS TREATMENT FOR RECURRENT GLIOBLASTOMA
14-1091Kavanagh, Brian
A RANDOMIZED PHASE II STUDY OF INDIVIDUALIZED COMBINED MODALITY THERAPY FOR STAGE III NON-SMALL CELL LUNG CANCER (NSCLC)RTOG 1306
07-0851Kavanagh, Brian D
RANDOMIZED PHASE III COMPARISON OF STANDARD DOSE (60 GY) VS HIGH DOSE (74 GY) CONFORMAL RADIOTHERAPY WITH CONCURRENT AND CONSOLIDATION CARBOPLATIN/PACLITAXEL +/- CETUXIMAB IN PATIENTS WITH STAGE IIIA/IIIB NON SMALL CELL LUNG CANCER
16-0812Kay, Joseph A
Bicuspid Valve Aortopathy Feasiblity Sub-Study: Cross Sectional Imaging
01-279Keith, Robert
A RANDOMIZED PHASE II CHEMOPREVENTION STUDY OF ILOPROST VERSUS PLACEBO IN PATIENTS AT HIGH RISK FOR LUNG CANCER
08-0715Keith, Robert
A RANDOMIZED PHASE II CHEMOPREVENTION STUDY OF PIOGLITAZONE VERSUS PLACEBO IN PATIENTS AT HIGH RISK FOR LUNG CANCER
15-2288Kelmenson, Lindsay E
Periodontal inflammation and immunity in preclinical RA
11-0521Kendrick, Jessica
Vitamin D and Arterial Function in Patients with Chronic Kidney Disease
13-2017Kendrick, Jessica
Effect of Treatment of Metabolic Acidosis on Vascular Function in Patients with Chronic Kidney Disease: A Pilot Study
14-0088Kerby, Gwendolyn
OPTIMIZing Treatment for Early Pseudomonas aeruginosa Infection in Cystic Fibrosis: The OPTIMIZE Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial (OPTIMIZE-IP-12)
14-1899Kerby, Gwendolyn
Saline Hypertonic in Preschoolers (SHIP001)
15-1877Kerr, Janice Marie M.D.
A PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE CONTROLLED, MULTICENTER STUDY TO EVALUATE MAINTENANCE OF RESPONSE, SAFETY AND PATIENT REPORTED OUTCOMES IN ACROMEGALY PATIENTS TREATED WITH OCTREOTIDE CAPSULES, AND IN PATIENTS TREATED WITH STANDARD OF CARE PARENTERAL SOMATOSTATIN RECEPTOR LIGANDS WHO PREVIOUSLY TOLERATED AND DEMONSTRATED A BIOCHEMICAL CONTROL ON BOTH TREATMENTS Protocol No. OOC-ACM-302 WIRB No. 20151957
14-0909Kessler, Elizabeth
An open label, randomized, Phase II trial of Metabolic complications in patients treated with enzalutamide vs standard ADT for the treatment of hormone sensitive prostate cancer
15-2372Kessler, Elizabeth Riley
A Phase 3, Multicenter, Multinational, Randomized, Open-Label, Parallel-Arm Study of Avelumab (MSB0010718C) Plus Best Supportive Care Versus Best Supportive Care Alone as a Maintenance Treatment in Patients with Locally Advanced or Metastatic Urothelial Cancer Whose Disease Did Not Progress After Completion of First-Line Platinum-Containing Chemotherapy. Sponsor No. B9991001. WIRB No. 20152463
16-0556Kim, Kevin Kwang Pyo
Screening Emergency Department Patients for Aberrant Drug-Related Behaviors
06-0124Kinsella, John
NON-INVASIVE INHALED NITRIC OXIDE IN PREMATURE NEWBORNS
16-0395Klein, Ulrich
Association of Tooth Anomalies and Heart Disease Among Pediatric Patients
10-0771Kluger, Benzi
COGNITIVE DYSFUNCTION IN PARKINSON'S DISEASE
13-1772Kluger, Benzi
A Pilot Investigation of Transcranial Magnetic Stimulation as Treatment for Cortical Hyperexcitability Syndromes
13-2724Kluger, Benzi
Cortical physiology as a therapeutic target in Parkinson's disease related dementia and cognitive dysfunction
15-1035Kluger, Benzi
Impact of transcranial direct current stimulation on fatigability and fatigue induced by a selective attention task
12-0315Knupp, Kelly
Compassionate Use of Stiripentol for the Treatment of Dravet Syndrome
15-1981Knupp, Kelly G
A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Trial of Two Fixed Doses of ZX008 (Fenfluramine Hydrochloride Oral Solution as an Adjunctive Therapy in Children and Young Adults with Dravet Syndrome Protocol No. ZX008-1501 WIRB No. 20152520
16-0364Knupp, Kelly G
Retrospective chart review of lorcaserin in children with Dravet syndrome
12-0389Kondapalli, Laxmi A
Oncofertility Patient Registry
00-236Kounalakis, Nicole
NSABP B-31 A RANDOMIZED TRIAL COMPARING THE SAFETY AND EFFICACY OF ADRIAMYCIN AND CYCLOPHOSPHAMIDE FOLLOWED BY TAXOL (AC-T) TO THAT OF ADRIAMYCIN AND CYCLOPHOSPHAMIDE FOLLOWED BY TAXOL PLUS HERCEPTIN (AC-T+H) IN NODE-POSITIVE BREAST CANCER PATIENTS WHO HAVE TUMORS THAT OVEREXPRESS HER2
06-0943Kounalakis, Nicole
A CLINICAL TRIAL TO DETERMINE THE EFFICACY OF FIVE YEARS OF LETROZOLE COMPARED TO PLACEBO IN PATIENTS COMPLETING FIVE YEARS OF HORMONAL THERAPY CONSISTING OF AN AROMATASE INHIBITOR (AI) OR TAMOXIFEN FOLLOWED BY AN AI IN PROLONGING DISEASE FREE SURVIVAL IN POST MENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE BREAST CANCER
07-0635Kounalakis, Nicole
RANDOMIZED PHASE III TRIAL OF NEOADJUVANT THERAPY FOR PATIENTS WITH PALPABLE AND OPERABLE HER2 POSITIVE BREAST CANCER COMPARING THE COMBINATION OF TRASTUZUMAB PLUS LAPATINIB TO TRASTUZUMAB AND TO LAPATINIB ADMINISTERED WITH WEEKLY PACLITAXEL FOLLOWING AC ACCOMPANIED BY CORRELATIVE SCIENCE STUDIES TO IDENTIFY PREDICTORS OF PATHOLOGIC COMPLETE RESPONSE
08-1266Kounalakis, Nicole
A PHASE III CLINICAL TRIAL COMPARING TRASTUZUMAB GIVEN CONCURRENTLY WITH RADIATION THERAPY AND RADIATION THERAPY ALONE FOR WOMEN WITH HER2-POSITIVE DUCTAL CARCINOMA IN SITU RESECTED BY LUMPECTOMY
15-1829Kowalski, Robert G
University of Colorado Status Epilepticus Outcomes Study
10-1234Krebs, Nancy
Iron Deficiency in Infants and Toddlers: Does Vitamin E Enhance Efficacy of Iron Treatment?
14-0150Kuwayama, David
Zenith® Low Profile AAA-LP Endovascular Graft clinical study (G080185/S028)
11-0126Lam, Elaine
S0925, "A Randomized Phase II Study of Androgen Deprivation Combined with IMC-A12 Versus Androgen Deprivation Alone for Patients with New Hormone-Sensitive Metastatic Prostate Cancer."
11-0545Lam, Elaine
S0931, "EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, a Phase III Study"
11-0655Lam, Elaine
A Phase 2 Study Acai Juice Product in Asymptomatic or Minimally Symptomatic Prostate Cancer Patients with Rising PSA
13-1489Lam, Elaine
Phase II Study of Abiraterone Acetate and Prednisone in Combination with Cabazitaxel, Compared to Cabazitaxel Alone, in Patients with Metastatic Castrate Resistant Prostate Cancer
13-1908Lam, Elaine
A Pilot Study to Enhance F18 FDG-PET Imaging of Prostate Cancers with the Metabolic Inhibitor Ranolazine
13-2053Lam, Elaine
A Phase II Study of Bevacizumab Alone or in Combination with TRC105 for Advanced Renal Cell Cancer. P2C 9144
11-0545Lam, Elaine Tat M.D.
S0931, "EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, a Phase III Study"
13-1546Lam, Elaine Tat M.D.
An International Phase 3, Randomized Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (ADAPT)
16-0215Lam, Elaine Tat M.D.
A Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects with Advanced or Metastatic Renal Cell Carcinoma WIRB No. 20152079
16-0224Lam, Elaine Tat M.D.
A PHASE 3, MULTINATIONAL, RANDOMIZED, OPEN-LABEL, PARALLEL-ARM STUDY OF AVELUMAB (MSB0010718C) IN COMBINATION WITH AXITINIB (INLYTA®) VERSUS SUNITINIB (SUTENT®) MONOTHERAPY IN THE FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA Protocol No. B9991003 WIRB no. 20152576
16-0581Lee, Joyce Sujin
University of Colorado Denver - Developing a Better Understanding of Interstitial Lung Disease (CU-BUILD)
15-0929Leehey, Maureen
A randomized, double blind, placebo-controlled crossover study of tolerability and efficacy of Cannabidiol (CBD) on tremor in Parkinson’s disease
15-2328Leehey, Maureen
A randomized, double-blind, placebo-controlled trial of urate-elevating inosine treatment to slow clinical decline in early Parkinson’s disease
15-0929Leehey, Maureen A M.D.
A randomized, double blind, placebo-controlled crossover study of tolerability and efficacy of Cannabidiol (CBD) on tremor in Parkinson’s disease
15-2328Leehey, Maureen A M.D.
A randomized, double-blind, placebo-controlled trial of urate-elevating inosine treatment to slow clinical decline in early Parkinson’s disease
10-0519Leong, Stephen
S0518:Phase III Prospective Randomized Comparison of Depot Octreotide Plus Interferon Alpha Versus Depot Octreotide Plus Bevacizumab (NSC#704865) In advanced, Poor Carcinoid Patients
10-1455Leong, Stephen
CALGB C80702, A Phase III Trial of Versus 12 Treatments of Adjuvant FOLFOX plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer
11-0426Levi, Marilyn
Compassionate Use Of Clofazimine For The Treatment Of Atypical Mycobacterial Infections
11-1438Levi, Marilyn
"Compassionate use of Triclabenazole for the Treatment of Parasites" (Prior to FDA Approval; Expanded Access Program)
15-1432Levin, Myron J M.D.
A Phase 2 Randomized, Double-Blind Study to evaluate the Efficacy of MEDI7510 for the Prevention of Acute Respiratory Syncytial Virus-associated Respiratory Illness in Older Adults. Sponsor Protocol No. D4420C00005 WIRB Protocol No. 20151473
16-1008Levy, Cari Renee M.D.
Evaluation of Mobile Emergency On Site Care in Colorado
13-2304Lewis, Karl
S1221, "Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination with Dabrafenib and Trametinib in Patients with BRAF Mutant Cancer"
14-0616Lewis, Karl
A Multicenter Phase II Trial of Intratumoral pIL-12 + Electroporation in Advanced Stage Cutaneous and In Transit Malignant Melanoma
15-2387Lewis, Karl Douglas M.D.
A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH – 1 (PD-1), IN PATIENTS WITH ADVANCED CUTANEOUS SQUAMOUS CELL CARCINOMA Sponsor No. R2810-ONC-1540. WIRB No. 20160256
15-0802Lieu, Christopher
A phase II, multicenter, single-arm study of oral ceritinib in adult patients with ALK and ROS1 activated gastrointestinal malignancies
14-1876Lillehei, Kevin
An Expanded Access Protocol for the Treatment of Glioblastoma Multiforme in Patients with Already Manufactured DCVax®-L, Autologous Dendritic Cells Pulsed with Tumor Lysate Antigen Who Have Screen-Failed Protocol 020221
15-2153Lillehei, Kevin O
Vigilant observatIon of GlIadeL WAfer ImplaNT (VIGILANT) Registry: A Multicenter, Observational Registry to Collect Information on the Safety and Efficacy of Gliadel® Wafer (Carmustine Implant) Used in Usual Medical Practice Sponsor Protocol No. AE22.001 WIRB Protocol No. 20152789
14-1917Lindberg, Daniel
Fast MR for Young Children with Traumatic Brain Injury
14-1909Lindley, Emily
A Double-Blind, Placebo-Controlled Crossover Study Comparing the Analgesic Efficacy of Cannabis versus Oxycodone
16-0875Luthy, Sarah Kim M.D.
Psychogenic Nonepileptic Seizures in Pediatric Patients
15-1353Maa, Edward Huei Tai MD
A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LACOSAMIDE AS ADJUNCTIVE THERAPY FOR UNCONTROLLED PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN SUBJECTS WITH IDIOPATHIC GENERALIZED ELILEPSY. Sponsor Protocol No. SP0982 WIRB Protocol No. 20150259
15-1355Maa, Edward Huei Tai MD
An open-label, multicenter extension study to evaluate the long-term safety and efficacy of lacosamide as adjunctive therapy for uncontrolled primary generalized tonic-clonic seizures in subjects with idiopathic generalized epilepsy. WIRB Protocol No. 20150295
11-1499Maahs, David
Early Diagnosis of Change in GFR in Adults and Adolescents with Type 1 Diabetes by Iohexol Clearance Using Dried Capillary Blood
13-2457Maahs, David
PERL: a multicenter clinical trial of allopurinol to prevent renal function (GFR) loss in type 1 diabetes
13-2759Maahs, David
Evaluation of Glucose Sensor and Insulin Infusion Set Failure: Lipohypertrophy Study
13-2818Maahs, David
Evaluation of Glucose Sensor and Insulin Infusion Set Failures: Hyaluronidase Study
14-0676Maahs, David
Hybrid Closed-Loop Hotel Studies with Medtronic PID Controller - Hotel HCL Study
15-2469Maahs, David
Reducing Risks and Improving Glucose Control during Extended Exercise in Youth with T1DM: The AP Ski Camp
16-0488Maahs, David M M.D.
A Randomized Crossover Study to Evaluate the Efficacy of Fault Detection Algorithms using the ZoneMPC Algorithm and DIAS System in Adult Subjects with Type 1 Diabetes in the Outpatient Setting
16-0920Maahs, David M M.D.
Remote Monitoring of Diabetes in Young Children with Type 1 Diabetes
14-0213Mack, Cara
THE EVALUATION OF THE INTESTINAL BILE ACID TRANSPORT (IBAT) INHIBITOR LUM001 IN THE REDUCTION OF PRURITUS IN ALAGILLE SYNDROME, A CHOLESTATIC LIVER DISEASE
14-1883Mack, Cara
A Multicentre Extension Study to Evaluate the Long-Term Safety and Durability of the Therapeutic Effect of LUM001, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi), in the Treatment of Cholestatic Liver Disease in Pediatric Subjects with Alagille Syndrome (IMAGINE II)
14-0977MacLaren, Robert
A Randomized, Double-Blind Study of Placebo vs. Famotidine and Esomeprazole for Stress Ulcer Prophylaxis: Associations Between Acid Suppression, Gastrointestinal Ulceration, and Microbiome Profiles
09-0352Macy, Margaret
A PHASE II STUDY OF EXTERNAL BEAM RADIATION THERAPY AND CETUXIMAB FOLLOWED BY IRINOTECAN AND CETUXIMAB FOR CHILDREN AND YOUNG ADULTS WITH NEWLY DIAGNOSED DIFFUSE PONTINE TUMORS AND HIGH GRADE ASTROCYTOMAS (POE08-01)
09-0814Macy, Margaret
A Phase II Study of Everolimus (RAD001) for Children with Chemotherapy and/or Radiation-Refractory Progressive or Recurrent Low-Grade Gliomas
10-0418Macy, Margaret
The Role of Bevacizumab in the Treatment of Radiation Induced Injury/Radiation Necrosis in Children with Central Nervous System Tumors
13-0053Macy, Margaret
An Open Label, Expanded Access Protocol using 131-I-Metaiodobenzylguanidine (131 I -MIBG) therapy in patients with refractory neuroblastoma, pheochromocytoma, or paraganglioma
13-1475Macy, Margaret
NANT N2008-02 Phase I study of vorinostat in combination with 13-cis-retinoic acid in patients with refractory/recurrent neuroblastoma
13-1893Macy, Margaret
NANT 2009-03:Phase I/II Study of MLN8237 in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma
13-3141Macy, Margaret
NANT 2012-01: Phase I Study of Difluoromethylornithine (DFMO) and Celecoxib with Cyclophosphamide/Topotecan For Patients With Relapsed or Refractory Neuroblastoma
14-1387Macy, Margaret
NANT 2011-01: Study of Single-Agent 131I-MIBG, 131I-MIBG with Vincristine and Irinotecan, or 131I-MIBG with Vorinostat for Resistant/Relapsed Neuroblastoma
14-1756Macy, Margaret
NANT 2013-02: A Phase I Study of Sorafenib and Cyclophosphamide/Topotecan in Patients with Relapsed and Refractory Neuroblastoma
14-1982Macy, Margaret
ADVL1322 (GSK VEG116731), A Phase II Study of Pazopanib (GW786034. NSC# 737754) in Children, Adolescents and Young Adults with Refractory Solid Tumors
15-0044Macy, Margaret
NANT 2014-01: Phase I Study of SF1126 for Patients with Relapsed or Refractory Neuroblastoma
16-0064Macy, Margaret
ADVL1621: A Phase I/II Study of Pembrolizumab (MK-3475) in Children with advanced melanoma or a PD-L1 positive advanced, relapsed or refractory solid tumor or lymphoma (KEYNOTE-051)
16-0064Macy, Margaret Ellen M.D.
ADVL1621: A Phase I/II Study of Pembrolizumab (MK-3475) in Children with advanced melanoma or a PD-L1 positive advanced, relapsed or refractory solid tumor or lymphoma (KEYNOTE-051)
16-0151Macy, Margaret Ellen M.D.
A Phase 1, Open-Label, Dose-Escalation Study of Olaratumab as a Single Agent and in Combination with Doxorubicin, Vincristine/Irinotecan, or High-Dose Ifosfamide in Pediatric Patients with Relapsed or Refractory Solid Tumors (Protocol 15B-MC-JGDN)
16-0216Macy, Margaret Ellen M.D.
Multicenter Cohort Study to Evaluate Outcomes after Receipt of Targeted Therapy Matched to an Individualized Cancer Therapy (iCat) Recommendations in Children and Young Adults with Recurrent, Refractory, or High Risk Solid Tumors: The iCat2, GAIN Consortium Study
06-1151Madden, Jennifer
FEASIBILITY OF USING CONCURRENT CARBOPLATIN AND REDUCED DOSE CRANIOSPINAL RADIATION (24 GY) FOR METASTATIC MEDULLOBLASTOMA AND HIGH-RISK SUPRATENTORIAL PNET AND METASTATIC PNET
16-0498Maddux, Aline M.
Pediatric Acute Respiratory Distress Syndrome Incidence and Epidemiology (PARDIE) Study
08-0312Maloney, Kelly
AALL07P2 PHARMACOLOGY AND TOXICITY OF ERWINIA ASPARAGINASE (ERWINASE®; CRISANTASPASE; IND 290) FOLLOWING ALLERGY TO PEG-ASPARAGINASE IN TREATMENT OF CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)
12-0700Maloney, Kelly
AALL1122-BMS ID CA180-372 Phase 2 Multi-Center, Historically-Controlled Study of Dasatinib (IND# 66,971) Added to Standard Chemotherapy in Pediatric Patients with Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)
13-2992Manco-Johnson, Marilyn
A Phase 3b Continuation Study of the Safety and Efficacy of PEGylated Recombinant Factor VIII (PEG-rFVIII; BAX855) in Prophylaxis of Bleeding in Previously Treated Patients with Severe Hemophilia A
14-0659Manco-Johnson, Marilyn
Pediatric High-Risk Deep Venous Thrombosis Lytic Outcomes (PHLO) Trial
07-0182Maroni, Paul
RANDOMIZED PHASE III STUDY OF NEO-ADJUVANT DOCETAXEL AND ANDROGEN DEPRIVATION PRIOR TO RADICAL PROSTATECTOMY VS IMMEDIATE RADICAL PROSTATECTOMY IN PATIENTS WITH HIGH RISK CLINICALLY LOCALIZED PROSTATE CANCER.
15-2089Maroni, Paul Daniel M.D.
A Phase 3 Study to Evaluate the Safety and Efficacy of 99mTc-MIP-1404 SPECT/CT Imaging to Detect Clinically Significant Prostate Cancer in Men with Biopsy Proven Low-Grade Prostate Cancer who are Candidates for Active Surveillance (proSPECT-AS) WIRB Protocol No. 20152588
11-0050Martiniano, Stacey
Compassionate use of Clofazimine (Lamprene®) - CCC
15-1153Martiniano, Stacey L.
A Phase 3, Randomized, Open-Label, Assessor-Blind, Non-Inferiority, Active-Comparator Study Evaluating the Efficacy and Safety of Liprotamase in Subjects with Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency. Sponsor Protocol No. AN-EPI3331. WIRB Protocol No.20151024
16-0558Martiniano, Stacey L.
Low IRT Levels and Characteristics of Persons with False Negative Newborn Screening Tests for Cystic Fibrosis in the United States
16-0533Mayer, Stephanie Watson M.D.
Comparison of Outcomes between Operative versus Non-Operative Treatment of Medial Epicondyle Fractures
16-0872Mazzoni, Sara E
A Randomized-Controlled Trial of MotherWise
02-607McCarter, Martin
ACOSOG Z9001: A PHASE III RANDOMIZED DOUBLE-BLIND STUDY OF ADJUVANT STI571 (GLEEVEC) VERSUS PLACEBO IN PATIENTS FOLLOWING THE RESECTION OF PRIMARY GASTROINTESTINAL STROMAL TUMOR (GIST)
06-0703McCarter, Martin
A CLINICAL TRIAL COMPARING PREOPERATIVE RADIATION THERAPY AND CAPECITABINE WITH OR WITHOUT OXALIPLATIN WITH PREOPERATIVE RADIATION THERAPY AND CONTINUOUS INTRAVENOUS INFUSION OF 5-FLUOROURACIL WITH OR WITHOUT OXALIPLATIN IN THE TREATMENT OF PATIENTS WITH OPERABLE CARCINOMA OF THE RECTUM.--NSABP PROTOCOL R-04 IND
09-0562McCarter, Martin
PHASE II, NON-RANDOMIZED, OPEN-LABEL MULTICENTER STUDY OF 5 YEAR ADJUVANT IMATINIB MESYLATE (GLEEVEC) IN PATIENTS AT SIGNIFICANT RISK FOR RECURRENCE FOLLOWING COMPLETE RESECTION OF PRIMARY GASTROINTESTINAL STROMAL TUMOR (GIST)
16-0620McCarter, Martin D. M.D.
A Randomized, Double-Blinded, Placebo-Controlled Trial of TU-100 in Patients Undergoing Laparoscopic Colectomy
15-2316McCoach, Caroline Elizabeth
Early Rebiopsy to Identify Mechanisms and Biomarkers of Tumor Cell Survival Following Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibito
14-1762McCourt, Emily
Binocular Computer Activities for Treatment of Amblyopia (ATS18)
16-0145McCourt, Emily A.
An Observational, Multicenter Study of the Prevalence of Cerebrotendinous Xanthomatosis (CTX) in Patient Populations Diagnosed with Early-Onset Idiopathic Bilateral Cataracts Sponsor Protocol No. 018CTXX15001 WIRB Protocol No. 20160376
16-0294McCourt, Emily A.
The Collection of Blood Samples from Patients With NF1 for Research Purposes. Sponsor Protocol Number CTF004. WIRB Protocol Number 20152188
15-0983McDevitt, Amy W D.P.T.
Title: Thoracic Spine Thrust Manipulation for Cervicogenic Headaches: A Randomized Clinical Trial
03-546McFarland, Elizabeth
IMPAACT P1026s: Pharmacokinetic Properties of Antiretroviral and Related Drugs During Pregnancy and Postpartum, Version 9.0
10-1504McFarland, Elizabeth
1077HS HAART Standard Version of the PROMISE Study (Promoting Maternal and Infant Survival Everywhere), Version 2.0
12-0124McFarland, Elizabeth
IMPAACT P1083: A Phase II/III Trial of Lopinavir/Ritonavir Dosed According to the WHO Pediatric Weight Band Dosing Guidelines, Version 1.0
12-0129McFarland, Elizabeth
IMPAACT P1097: Raltegravir Pharmacokinetics and Safety in Neonates, Version 2.0
12-0298McFarland, Elizabeth
IMPAACT P1093: Phase I/II, Multi-Center, Open-Label Pharmacokinetic, Safety, Tolerability and Antiviral Activity of GSK1349572, a Novel Integrase Inhibitor, in Combination Regimens in HIV-1 Infected Infants, Children and Adolescents, Version 3.0
12-1357McFarland, Elizabeth
A Phase IV Randomized Trial to Evaluate the Virologic Response and Pharmacokinetics of Two Different Potent Regimens in HIV Infected Women Initiating Triple Antiretroviral Regimens Between 28 and 36 Weeks of Pregnancy for the Prevention of Mother-to-Child Transmission: NICHD P1081, Version 3.0
13-3234McFarland, Elizabeth
IMPAACT P1114: A Phase I Study of the Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine RSV cps2, Lot RSV#005A, Delivered as Nose Drops to RSV-Seronegative Infants and Children 6 to 24 Months of Age, Version 1.0
16-0531McFarland, Elizabeth J M.D.
IMPAACT 2011: Phase I Placebo-Controlled Study of the Infectivity, Safety and Immunogenicity of a Single Dose of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, LID ΔM2-2 1030s, Lot RSV#010A, Delivered as Nose Drops to RSV-Seronegative Infants 6 to 24 Months of Age, Version 1.0
16-0509Mehta, Pooja
Adherence to dietary therapy in adolescent patients with eosinophilic esophagitis – a qualitative study
13-0142Mei Dan, Omer
A Randomized Clinical Trial Evaluating Platelet Rich Plasma versus Hyaluronic-Acid in the short-term Treatment of Symptomatic OA (Osteoarthritis) of the Hip
15-2067Melanson, Edward L PhD
Cold induced thermogenesis and brown adipose tissue activity in post-menopausal women
05-1014Messersmith, Wells
SWOG E5202, A RANDOMIZED PHASE III STUDY COMPARING 5-FU, LEUCOVORIN AND OXALIPLATIN VS. 5-FU, LEUCOVORIN, OXALIPLATIN AND BEVACIZUMAB IN PATIENTS WITH STAGE II COLON CANCER AT HIGH RISK FOR RECURRENCE TO DETERMINE PROSPECTIVELY THE PROGNOSTIC VALUE OF MOLECULAR MARKERS
15-2088Messersmith, Wells
Protocol for PF 03084014 in Patients with Advanced Solid Tumor Malignancies: Continuing Study Drug Administration in Desmoid Patients Receiving Clinical Benefit
15-2088Messersmith, Wells Alton
Protocol for PF 03084014 in Patients with Advanced Solid Tumor Malignancies: Continuing Study Drug Administration in Desmoid Patients Receiving Clinical Benefit
16-0912Metz, Torri Derback
EXPANDED NONINVASIVE GENOMIC MEDICAL ASSESSMENT: THE ENIGMA STUDY. (PRO-102-ENIGMA)
92-382Miller, James
ASSESSMENT OF INTERMEDIATE ENDPOINT BIOMARKERS TO 13 CISRETINOIC ACID WITH OR WITHOUT ALPHATOCOPHEROL
14-1247Miller, James York E M.D.
A Phase I Trial of Inhaled Iloprost for the Prevention of Lung Cancer in Former Smokers
16-0390Mistry, Rakesh D MD, MS
RNA Biosignatures: A Paradigm Change for the Management of Young Febrile Infants (Biosig II)
12-1653Moine, Pierre Andre
Adequacy of Perioperative Cefazolin for Surgery Antibiotic Prophylaxis in Obese Patients
15-2206Monteith, Lindsey L
Women Veterans’ Military Experiences and Perceptions of VHA Care
15-1665Montero, Paul
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of the XaraColl® Bupivacaine Implant (300 mg Bupi
16-0874Moore, Alia M.D.
The First Two Weeks: A PhotoVoice Study of Health After Release From Corrections
00-979Moore, Ernest
Preoperative Hypertonic Saline Attenuates Postoperative PMN Priming Following Major Elective Surgery
12-1349Moore, Ernest
Control of Major Bleeding After Trauma (COMBAT): A prospective, randomized comparison of fresh frozen plasma versus standard crystalloid intravenous fluid as initial resuscitation fluid
14-1803Moore, Ernest
Clinical Assessment of the Management of Suprahepatic IVC Injuries
16-0351Moore, Jaime Megan
Prevalence of Obesity, Pre-Hypertension, and Hypertension among Children with Congenital Heart Disease
06-0537Moreau, Kerrie
BIOLOGICAL MECHANISMS OF VASCULAR DYSFUNCTION WITH AGE AND ESTROGEN DEFICIENCY
14-0532Moreau, Kerrie
The effects of resveratrol and acute exercise on endothelial function in postmenopausal women
15-1162Moreau, Kerrie
Cardiovascular consequences of hypogonadism in men
12-0064Moss, Marc
Prospective Validation of a Plasma Transfusion Dosing Algorithm in Patients with Chronic Liver Disease
16-0806Moulton, Steven L. M.D.
Evaluation of the Compensatory Reserve Index with Tilt Table Tests
16-0378Mounessa, Jessica S
Investigating morphological changes in serotonin reuptake inhibitor-induced alopecia
12-1528Nadeau, Kristen
Effects of metformin on cardiovascular function in adolescents with type-1 diabetes.
13-0122Nadeau, Kristen
RISE: The Restoring Insulin Secretion Pediatric Medication Study.
13-2059Nadeau, Kristen
Metformin Therapy for Overweight Adolescents with T1D
15-2420Nair, Kavita Venugcpal PhD
Real World Effectiveness of First-Line Use of Gilenya: A Two-Site Retrospective Study
15-1673Narayan, Anne Katherine
Does the expectation of pain with intrauterine device (IUD) insertion differ between those who uptake IUD’s and those who do not?: A survey of adolescents and young adult women
15-0815Narkewicz, Michael R
An Open-Label, Multicenter Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Ombitasvir (OBV), Paritaprevir (PTV), Ritonavir (RTV) With or Without Dasabuvir (DSV) and With or Without Ribavirin (RBV) in Pediatric Subjects with Genotype 1 or 4 Chronic Hepatitis C Virus (HCV) Infection Sponsor Protocol No. M14-748 WIRB Protocol No. 20151452
15-2247Narkewicz, Michael R
A Long Term Follow-up Registry for Adolescent and Pediatric Subjects Who Received a Gilead Hepatitis C Virus Direct Acting Antiviral (DAA) in Gilead Sponsored Chronic Hepatitis C Infection Trials Sponsor Protocol No. GS-US-334-1113 WIRB Protocol No. 20151475
15-2004Nehler, Mark
An international, multicenter, randomized, double-blind, placebo-controlled phase 3 trial investigating the efficacy and safety of rivaroxaban to reduce the risk of major thrombotic vascular events in patients with symptomatic peripheral artery disease undergoing lower extremity revascularization procedures (Voyager)
15-2004Nehler, Mark Richard
An international, multicenter, randomized, double-blind, placebo-controlled phase 3 trial investigating the efficacy and safety of rivaroxaban to reduce the risk of major thrombotic vascular events in patients with symptomatic peripheral artery disease undergoing lower extremity revascularization procedures (Voyager)
13-2436Neumann, Robert
Physiological Effects of Intrathoracic Pressure Regulation in Patients with Decreased Cerebral Perfussion Due to Brain Injury or Intracranial Pathology
10-0274Ney, Douglas
A Pilot Phase II Trial of Hypofractionated Intensity-Modulated Radiation Therapy (Hypo-IMRT) Combining with Temozolomide (TMZ) and Bevacizumab for Patients with Newly Diagnosed Glioblastoma Multiforme (GBM)
16-0983Niermeyer, Susan
VentFirst: A Multicenter RCT of Assisted Ventilation During Delayed Cord Clamping for Extremely Preterm Infants
15-1610Noonan, Amanda Golzar
Analysis of already collected genetic data from public databases
13-1396Nydam, Trevor
A Phase II Randomized Multicenter Placebo-Controlled Blinded Study of Sorafenib Adjuvant Therapy in High Risk Orthotopic Liver Transplant (OLT) Recipients with Hepatocellular Carcinoma (HCC)
11-0366Oliver, Scott
A PROSPECTIVE PILOT STUDY OF SURGICAL RADIATION SHIELDING WITH VITRECTOMY AND SILICONE OIL TAMPONADE FOR THE PROTECTION OF RADIATION-INDUCED OCULAR INJURY IN THE TREATMENT OF CHOROIDAL MELANOMA WITH RADIOACTIVE IODINE-125 PLAQUE BRACHYTHERAPY
14-0632Overholser, Linda
Low-dose Tamoxifen For Radiation-Induced Breast Cancer Risk Reduction: A Phase IIB Randomized Placebo-Controlled Trial
15-2101Palestine, Alan G
A Phase 3, Randomized, Masked, Controlled Clinical Trial to Study the Safety and Efficacy of Triamcinolone Acetonide Injectable Suspension (CLS-TA) for the Treatment of Subjects with Macular Edema Associated with Non-Infectious Uveitis Sponsor Protocol No. CLS1001-301 WIRB Protocol No. 20152662
16-0469Park, Kristen L
Epilepsy Genetics Initiative (EGI)
10-1425Parsons, Julie
An Open-label, Safety Study for Previously Treated Ataluren (Ptc124) Patients with Nonsense Mutation Dystrophinopathy
14-1328Parsons, Julie
A Phase 3, Randomized, Double-blind, Sham-Procedure Controlled Study to Assess the Clinical Efficacy and Safety of ISIS 396443 Administered Intrathecally in Patients with Infantile-onset Spinal Muscular Atrophy
14-1684Parsons, Julie
A PHASE 3 EXTENSION STUDY OF ATALUREN (PTC124) IN PATIENTS WITH NONSENSE MUTATION DYSTROPHINOPATHY
07-0074Patel, Vikas
CLINICAL STUDY TO EVALUATE THE SAFETY AND EFFECTIVENESS OF THE AESCULAP ACTIV-L ARTIFICIAL DISC IN THE TREATMENT OF DEGENERATIVE DISC DISEASE
14-0905Paxton, Roger
Alterations in skeletal muscle gene expression following total knee arthroplasty
16-0541Pelanda, Roberta Ph.D.
Analysis of B cells from autoimmune individuals
15-1103Peterson, Melissa Brooks M.D.
Dexmedetomidine use for Anesthesia in patients undergoing Selective Fetoscopic Laser Photocoagulation (SFLP) for operative treatment of Twin-Twin Transfusion Syndrome (TTTS): A Single Center Experience
13-3062Pieracci, Fredric
A Randomized Clinical Trial of 4 vs. 8 Days of Definitive Antibiotic Therapy for Early Ventilator-Associated Pneumonia in the Surgical Intensive Care Unit: The Duration of Antibiotic Treatment for Early VAP (DATE) Trial (NCT01994980)
14-0167Pieracci, Fredric
A Randomized Controlled Pilot Study of Goal-directed Iron Supplementation of Anemic, Critically Ill Surgical Patients with Functional Iron Deficiency, with and without Oxandrolone (NCT02047552)
12-1283Pollyea, Daniel
Sequential Treatment with Azacitidine and Lenalidomide for Relapsed and Refractory Patients with Acute Myeloid Leukemia
12-1558Pollyea, Daniel
A Phase 2 Study of PF-04449913 for the Treatment of Acute Leukemia Patients with High-Risk of Post-Allogenic Stem Cell Transplantation Relapse
12-1559Pollyea, Daniel
SWOG 1117 - A Randomized Phase II/III Study of Azacitadine in Combination with Lenalidomide (NSC-703813) vs. Azacitadine Alone vs. Azacitadine in Combination with Vorinostat (NSC-701852) for Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)
13-0110Pollyea, Daniel
A Dose Escalation Study of Ibrutinib with Lenalidomide for Relapsed and Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
08-0786Polotsky, Alex
PREGNANCY IN POLYCYSTIC OVARY SYNDROME II (PPCOS II): A 25-WEEK, DOUBLE-BLINDED, RANDOMIZED TRIAL OF CLOMIPHENE CITRATE AND LETROZOLE FOR THE TREATMENT OF INFERTILITY IN WOMEN WITH POLYCYSTIC OVARY SYNDROME THE PURPOSE OF THIS STUDY IS TO DETERMINE WHICH OF THESE TWO MEDICATIONS, CLOMIPHENE CITRATE (CLOMID) OR LETROZOLE (FEMARA), WILL MOST LIKELY RESULT IN PREGNANCY AND A LIVE BIRTH IN WOMEN WITH PCOS
10-0547Polotsky, Alex
ASSESSMENT OF MULTIPLE INTRAUTERINE GESTATIONS FROM OVARIAN STIMULATION
11-0293Polotsky, Alex
Estrogen Sensitivity and Ovulatory Dysfunction in Obesity
12-1273Potter, Huntington
Pilot Phase 2 Trial of the Safety & Efficacy of GM-CSF (Leukine) in the Treatment of Alzheimer's Disease
13-2819Prager, Jeremy
Treatment of tracheostomy granulomas
07-0677Purcell, William
CTSU/E1505 - A PHASE III RANDOMIZED TRIAL OF ADJUVANT CHEMOTHERAPY WITH OR WITHOUT BEVACIZUMAB FOR COMPLETELY RESECTED STAGE IB-IIIA NON-SMALL CELL LUNG CANCER.
10-1453Purtle, Steven
Evaluation Of Two Plasma Transfusion Strategies In Bleeding Critically Ill Patients With Chronic Liver Disease
14-2157Quan, Dianna
Patient Assisted Intervention for Neuropathy: Comparison of Treatment in Real Life Situations (PAIN-CONTRoLS)
15-1259Quan, Dianna M.D.
A Multicenter, Open-Label, Extension Study to Evaluate the Long-Term Safety and Efficacy of Patisiran in Patients with Familial Amyloidotic Polyneurop Sponsor Protocol No. ALN-TTR02-006 WIRB Protocol No. 20152311
11-0913Quinones, Ralph
NMDP/CIBMTR PROTOCOL 10-CBA: A MULTI-CENTER ACCESS AND DISTRIBUTION PROTOCOL FOR UNLICENSED CRYOPRESERVED CORD BLOOD UNITS (CBUs) FOR TRANSPLANTATION IN PEDIATRIC AND ADULT PATIENTS WITH HEMATOLOGIC MALIGNANCIES AND OTHER INDICATIONS
12-0095Quinones, Ralph
Protocol 6637 - A Multicenter safety study of unlicensed, investigational cryopreserved cord blood units (CBUs) manufactured by the National Cord Blood Program (NCBP) and provided for unrelated hematopoietic stem cell transplantation of pediatric and adult patients
02-182Rabinovitch, Rachel
RTOG 96-01 A PHASE III TRIAL OF RADIATION THERAPY WITH OR WITHOUT CASODEX IN PATIENTS WITH PSA ELEVATION FOLLOWING RADICAL PROSTATECTOMY FOR PT3NO CARCINOMA OF THE PROSTATE.
04-0991Rabinovitch, Rachel
RTOG 0234 - A PHASE II RANDOMIZED TRIAL OF SURGERY FOLLOWED BY CHEMORADIOTHERAPY PLUS C225 (CETUXIMAB) FOR ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK
06-0829Rabinovitch, Rachel
RTOG 0417: A PHASE II STUDY OF BEVACIZUMAB IN COMBINATION WITH DEFINITIVE RADIOTHERAPY AND CISPLATIN CHEMOTHERAPY IN UNTREATED PATIENTS WITH LOCALLY ADVANCED CERVICAL CARCINOMA
16-0057Raghavan, Sridharan
Coronary artery disease burden and diabetes: relationship between glycemic control and myocardial infarction risk
10-0644Rasouli, Neda
Exscel (exenatide study of cardiovascular event lowering trial): a randomized, placebo controlled clinical trial to evaluate cardiovascular outcomes after treatment with exenatide once weekly in patients with type 2 diabetes mellitus
10-1191Rasouli, Neda
Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results a Long-Term, Multi-Centre, International, Randomized Double-Blind, Placebo-Controlled Trial to Determine Liraglutide Effects on Cardiovascular Events
13-0131Rasouli, Neda
GRADE: The Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study.
13-0317Rasouli, Neda
A long -term, randomized, double-blinded, placebo-controlled, multinational, multi-centre trial to evaluate cardiovascular and other long-term outcomes with semaglutide in subjects with type with type 2 diabetes.
14-0303Rasouli, Neda
DEVOTE: A Trial comparing cardiovascular safety of insulin degludec versus insulin glargine in subjects with type 2 diabetes at high risk of cardiovascular events.
14-0433Rasouli, Neda
INTARCIA DUROS: A Randomized, Multicenter Study to Evaluate Cardiovascular Outcomes with ITCA 650 in Patients Treated with Standard of Care for Type 2 Diabetes
14-0484Rasouli, Neda
Linagliptin Inpatient Trial: A Randomized Controlled Trial on the Safety and Efficacy of Linagliptin (Tradjenta®) Therapy for the Inpatient Management of General Surgery Patients with Type 2 Diabetes
14-2402Rasouli, Neda
D2D: Vitamin D and type 2 diabetes
15-2233Rasouli, Neda
Glycemic control and treatment satisfaction using Finesse versus pen for initiating bolus insulin dosing in type 2 diabetes mellitus patients not achieving glycemic targets on basal insulin with/without anti-hyperglycemic agents
15-2349Rasouli, Neda M.D.
PIONEER 3 - vs. DPP-4 inhibitor Efficacy and long-term safety of oral semaglutide versus sitagliptin in subjects with type 2 diabetes
13-1874Reece, T.
PERCEVAL S SUTURELESS HEART VALVE
15-1000Reece, T.
A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Preoperative Antithrombin Supplementation in Patients Undergoing High-Risk Cardiac Surgery with Cardiopulmonary Bypass
16-0352Reeder, Blaine Patrick
Analyzing Pain in Electronic Health Data to Improve Patient Care Quality
13-2015Regensteiner, Judith
Impact of sitagliptin on cardiovascular exercise performance in type 2 diabetes
15-1016Regner, Michael
Insular inhibitory neuromodulation to reduce cigarette craving and alter brain function in smokers
11-0905Reirden, Daniel
AMC 072: Protective Effect of Quadrivalent Vaccine in Young HIV-Positive Males Who Have Sex with Males, Version 5.0
12-1569Reirden, Daniel
ATN 110: Project PrEPare - An Open Label Demonstration Project and Phase II Safety Study of Pre-exposure Prophylaxis Use among Young Men Who Have Sex with Men (YMSM) in the United States, Version 3.0 / ATN 113 Project PrEPare - An Open Label Demonstration Project and Phase II Safety Study of Pre-exposure Prophylaxis Use among 15 to 17 Year Old Young Men Who Have Sex with Men (YMSM) in the United States, Version 2.0
13-3233Reirden, Daniel
MTN-023 / IPM 030: Phase 2a Safety Study of a Vaginal Ring Containing Dapivirine in Adolescent Females, Version 2.0
16-1145Reiter, Pamela D.
Dwindle- dose epinephrine in the pediatric intensive care unit
16-0680Rewers, Marian J M.D. PhD
Genome Sequencing in Diabetes Autoimmunity Study in the Young (DAISY)
16-0382Rhodes, Jason T M.D.
Post-operative change in foot progression angle in children with cerebral palsy
04-0567Ringel, Steven
Use Of 3,4-Diaminopyridine (3,4-Dap) In The Treatment Of Lambert-Eaton Syndrome (Lems)
12-1524Ringel, Steven
HDE Post-Approval Study (PAS) of NeuRx DPS for ALS
15-0254Roach Jr., Robert
Three New Ideas to Protect Special Forces from the Stress of High Altitude
15-0537Rochon, Paul J M.D.
Predicting the Safety and Effectiveness of Inferior Vena Cava Filters (PRESERVE) Sponsor Protocol No. G140045 P WIRB Protocol No. 20150996
14-0976Rogers, Robert
Randomized, Multicenter, Controlled Trial to Compare Best Endovascular versus Best Surgical Therapy in Patients with Critical Limb Ischemia (BEST-CLI Trial)
15-0756Rogers, Robert
Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial (CREST 2)
13-1620Ross, Michael
GORE Septal Occluder Clinical Study: A Study to evaluate safety and efficacy in the treatment of transcatheter closure of ostium secundum atrial septal defects (ASDs)
16-0319Ross, Michael Marshall
Comprehensive assessment of coronary artery compression during RV-PA conduit expansion
04-0678Ross, Randal
DOUBLE-BLIND TRIAL OF CHOLINE DURING PREGNANCY AND RISK FOR SCHIZOPHRENIA
16-0200Rusthoven, Chad
RTOG 3508/AbbVie M13-813, A Randomized, Placebo Controlled Phase 2b/3 Study of ABT-414 with Concurrent Chemoradiation and Adjuvant Temozolomide in Subjects with Newly Diagnosed Glioblastoma (GBM) with Epidermal Growth Factor Receptor (EGFR) Amplification (Intellance 1). Sponsor No. RTOG 3508/AbbVie M13-813. WIRB No. 20160178
13-1557Sagel, Scott
A Multi-Center, Randomized, Controlled, Double-Blind Study of the Effects of an Antioxidant-Enriched Multivitamin Supplement on Inflammation and Oxidative Stress in Cystic Fibrosis Patients.
14-2010Sagel, Scott
A Two-Part Multicenter Prospective Longitudinal Study of CFTR-Dependent Disease Profiling in Cystic Fibrosis (PROSPECT)
15-0575Sagel, Scott D MD, PhD
Reproductive and Sexual Health Issues in Young Women with CF: A Patient Survey
15-1238Sands Braverman, Rebecca
Retrospective Chart Review Determining Ocular Outcomes in Pediatric Patients Who Have Received Hematopoietic Stem Cell Transplantation
16-0214Santoro, Nanette F MD
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RAD1901 IN POSTMENOPAUSAL WOMEN WITH MODERATE TO SEVERE VASOMOTOR SYMPTOMS. Protocol No. VMRAD1901-203; WIRB Protocol No.20152538
16-0347Santoro, Nanette F MD
Reproductive Endocrinology and Infertility Research Recruitment Registry
10-1393Schauer, Irene
EFFECTS OF SERUM FATTY ACID LOWERING ON INSULIN SENSITIVITY, CARDIOVASCULAR FUNCTION, AND EXERCISE CAPACITY IN NON-INSULIN DEPENDENT DIABETES
15-1309Schauer, Irene
Bromocriptine QR as adjunct therapy in Type 1 Diabetes
16-0156Schreiner, Teri L
NAtalizumab for Prevention of Post-partum Relapses in patients with Multiple Sclerosis (NAPPREMS)
16-0635Schreiner, Teri L
Attitudes towards cannabis consumption in adolescents with multiple sclerosis
02-744Schrier, Robert
EFFICACY OF AGGRESSIVE RENIN-ANGIOTENSIN-ALDOSTERONE AXIS BLOCKADE IN PREVENTING/SLOWING RENAL FUNCTION DECLINE IN ADPKD
07-1215Schwartz, Robert
Pioglitazone and Exercise Effects on Older Adults with Mild Cognitive Impairment and Metabolic Syndrome
16-1084Scott, Frank I
Title Preliminary data collection for determining delays in anti-TNF administration
15-2350Seeberger, Lauren C
A PHASE III,MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, ACTIVE-CONTROLLED STUDY COMPARING THE EFFICACY AND SAFETY OF GASTRIC RETENTIVE, CONTROLLED RELEASE ACCORDION PILL™CARBIDOPA/LEVODOPA (AP-CD/LD) TO IMMEDIATE RELEASE CD/LD IN FLUCTUATING PARKINSON’S DISEASE PATIENTS, Protocol No. IN 11 004, WIRB No. 20152164
15-1972Seibold, Leonard K.
The Diurnal and Nocturnal Effect of Pilocarpine on Intraocular Pressure and Ocular Perfusion Pressure
14-1650Shah, Raj Jay M.D.
Multicenter, open-label, randomized, controlled phase III clinical study of the efficacy and safety of photodynamic therapy using porfimer sodium for injection as treatment for unresectable advanced perihilar cholangiocarcinoma Sponsor Protocol No. PIN-PHO1201 WIRB Protocol No. 20140456
14-2091Shah, Viralkumar
A Randomized Trial Comparing Continuous Glucose Monitoring With and Without Routine Blood Glucose Monitoring in Adults with Type 1 Diabetes
16-0326Shimamoto, Karen Emi
Collision injury patterns in high school ice hockey players
15-2378Simoes, Eric A
Feasibility Study: Tracking Community Mortality Due to Respiratory Syncytial Virus
12-0398Simpson, Jennifer
Platelet-Oriented Inhibition In New TIA and Minor Ischemic Stroke (POINT) Trial
14-2183Singh, Jasleen
Analysis of cataract surgery outcomes performed at the Children's Hospital Colorado from January 2005 through October 2014
15-1857Slover, Robert
ACCU-CHEK® CONNECT AT SCHOOL (CATS) PEDIATRIC STUDY
15-0684Slover, Robert H. M.D.
In-Clinic Feasibility Study to Observe the Closed Loop System. Sponsor Protocol No. CEP273/Z25. WIRB Protocol No. 20130443
15-2204Soden, Jason S M.D.
A Prospective, Randomized, Controlled, Double-Blind, Parallel-Group, Phase 3 Study to Compare Safety and Efficacy of Smoflipid 20% to Intralipid 20% in Hospitalized Neonates and Infants Requiring 28 Days of Parenteral Nutrition; Sponsor Protocol No: SMOF-018-CP3 WIRB no. 20152595
05-0407Sokol, Ronald
A RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED TRIAL OF CORTICOSTEROID THERAPY FOLLOWING PORTOENTEROSTOMY IN INFANTS WITH BILIARY ATRESIA
13-0400Sokol, Ronald
A Phase1/2A Trial of Intravenous Immunoglobulin (IVIG) Therapy Following Portoenterostomy in Infants with Biliary Atresia (PRIME)
06-1084Steck, Andrea
ORAL INSULIN FOR PREVENTION OF DIABETES IN PATIENTS AT RISK FOR TYPE 1 DIABETES
16-0233Stevens Lapsley, Jennifer E PT, PhD
Arthrofibrosis Following Total Knee Replacement
16-0279Stewart, Alejandra Maria
The Study of Hypermotor Seizures in Children
14-0744Stidham, Timothy
Age of Blood in Children in Pediatric Intensive Care Units (ABC-PICU)
15-2302Striebich, Christopher C M.D.
A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy and Safety of Two Doses of Anifrolumab in Adult Subjects with Active Systemic Lupus Erythematosus Protocol No. 2014-004633-96 Sponsor Protocol No. D3461C00005 WIRB Protocol No. 20150883
15-2303Striebich, Christopher C M.D.
A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy and Safety of Two Doses of Anifrolumab in Adult Subjects with Active Systemic Lupus Erythematosus Sponsor Protocl No. D3461C00005 WIRB Protocol No. 20152282
16-0134Striebich, Christopher C M.D.
An Investigator-Initiated, Phase II, Randomized, Withdrawal Study of Mycophenolate Mofetil (MMF) in Patients with Stable, Quiescent Systemic Lupus Erythematosus (SLE)
16-0776Su, Emily J 7244144
PRO-104-PREECLAMPSIA: COLLECTION OF SAMPLES FROM PREGNANT WOMEN FOR THE EVALUATION OF PREECLAMPSIA (PRE-E) BIOMARKERS
09-1203Sundaram, Shikha
Ursodeoxycholic Acid (UDCA) Therapy Pediatric Primary Sclerosing Cholangitis: A Pilot Withdrawal/Reinstitution Trial
11-0874Tartaglia, Nicole
Psychological and Motor Effects of Testosterone Therapy in Adolescent Males with Klinefelter Syndrome
10-0753Taylor, Matthew
Gzgd02607: A Phase 3, Randomized, Multi-Center, Multi-National, Open-Label, Active Comparator Study to Evaluate the Efficacy and Safety of GENZ-112638 in Patients With Gaucher Disease Type 1 who have Reached Therapeutic Goals with Enzyme Replacement Therapy (ENCORE)
13-2707Taylor, Matthew
Vanish Study Phase II Randomized, Placebo-Controlled, Double Blind Clinical Trial of Valsartan for Attenuating Disease Evolution in Early Sarcomeric HCM
10-0013Teal, Stephanie
A Multi-center, Open-Label, Randomized Parallel Group Study to Evaluate the Effects on the Mechanisms of Contraceptive Efficacy and, Secondarily, to Assess the Pharmacokinetic Profile and Safety of Two Progestin-Only Patches Containing Different Doses of Levonorgestrel (LNG) CCN009
13-2665Teal, Stephanie
CCN013. A phase IIb randomized, double blind, comparative study to assess the efficacy, safety, tolerability and inhibition of ovulation of two continuous regimens of oral daily 5 mg or 10 mg of ulipristal acetate (UPA), versus a dose of 5.0mg UPA for 24/4 days
13-3264Teal, Stephanie
Comparison of the Levonorgestrel IUD and the Copper IUD Placed in the Immediate Postplacental Period: A Prospective Cohort Study
15-0468Teal, Stephanie
Levonorgestrel Intrauterine System for Emergency Contraception
16-0560Teal, Stephanie
Nitrous Oxide versus IV Sedation for Anesthesia (NOVIA)
16-0560Teal, Stephanie Beth M.D.
Nitrous Oxide versus IV Sedation for Anesthesia (NOVIA)
16-0842Tester, PI
808 testing
15-0650Tregellas, Jason
Nicotinic agonist effects on BMI and neuronal response in overweight/obese adults
08-1376Van Hove, Johan
OXIDATIVE STRESS MARKERS IN INHERITED HOMOCYSTINURIA AND THE IMPACT OF TAURINE
15-1010Van Hove, Johan Lodewijk
The clinical utility of new mitochondrial functional tests
16-0397Vemulakonda, Vijaya M
Variations in adherence to AUA Guidelines on cryptorchidism in pediatric patients
16-0263Villalobos, Victor M
A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of ABBV-085, an Antibody Drug Conjugate, in Subjects with Advanced Solid Tumors. Sponsor No. M15-394. WIRB No. 20160879
16-0308Villalobos, Victor M
A PHASE 2-3, MULTICENTER, RANDOMIZED, DOUBLEBLIND STUDY OF SELINEXOR (KPT-330) VERSUS PLACEBO IN PATIENTS WITH ADVANCED UNRESECTABLE DEDIFFERENTIATED LIPOSARCOMA (DDLS) Sponsor Protocol No. KCP-330-020 WIRB Protocol No. 20152151
14-1856Vinogradskiy, Yevgeniy
Functional Avoidance Radiation Therapy for Lung Cancer Patients
10-1143Vollmer, Timothy
A Phase II, Double Blinded, Active Comparator, Randomized, Five Year Study Comparing Rituximab Induction Therapy Followed By Glatiramer Acetate Therapy to Glatiramer Acetate Monotherapy In Patients With Relapsing Multiple Sclerosis
14-0558Wadwa, Raj
Open-Label, Multicenter, Multiple Oral Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents >10 to &lt18 yrs of age with Type 2 Diabetes Mellitus and Currently on a Stable dose of Metformin
16-0241Wadwa, Raj Paul M.D.
Efficacy and Safety of Faster-acting Insulin Aspart compared to NovoRapid both in Combination with Insulin Degludec in Children and Adolescents with Type 1 Diabetes Protocol No. NN1218-4101 WIRB protocol no. 20160862
14-0718Wagner, Anne
A multicenter, multinational, randomized, controlled, assessor blinded study, performed in subjects with thermal burns, to evaluate the efficacy and safety of NexoBrid compared to Gel Vehicle, and compared to Standard of Care
16-0760Wagner, Anne M.D.
Ambulation in the Adult Burn Population: Perception versus Actuality.
16-0768Wamboldt, Marianne Z M.D.
A pilot study evaluating the utility of pharmacogenomic testing (GeneSight®) as a guide for selecting psychotropic medication for pediatric patients
14-0857Wang, Michael
A Phase III Open Label, Multicenter, Extension Study to assess the Safety and Efficacy of Recombinant Coagulation Factor VIII (rVIII-SingleChain, CSL627) in Subjects with Severe Hemophilia A
16-0348Wang, Michael M.D.
A Randomized, Multicenter, Open-Label, Phase III Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic RO5534262 Versus No Prophylaxis in Hemophilia A Patients with Inhibitors
14-1711Wani, Sachin
Comparison of traditional back-loaded fiducial needles with preloaded fiducial needles in EUS-guided fiducial marker placement for image-guided radiation therapy in patients with pancreatic cancer: A multicenter randomized controlled trial.
15-1600Wani, Sachin
Stent vs. Indomethacin for Preventing Post-ERCP Pancreatitis: The SVI Trial
1 - 600Next